Introduction {#s1}
============

Angiogenesis involves extensive remodelling of the extracellular matrix (ECM) and endothelial cells (ECs) ([@bib73]). The ECM is important for dynamic and multifunctional regulation of cell behaviours and can modulate the bioavailability and activity of growth factors, cytokines, and extracellular enzymes ([@bib1]). In addition, ECM proteins directly interact with cell surface receptors to activate signal transduction ([@bib14]). Matricellular proteins are ECM proteins that do not contribute directly to the formation of these structures in vertebrates but are involved in cell--matrix interactions and other diverse cellular functions ([@bib13]). Such proteins include thrombospondin-1, osteonectin, and members of the CYR61/CTGF/NOV (CCN) family of proteins ([@bib52]). Within the CCN protein family, cysteine-rich angiogenic inducer 61 (CYR61, also known as CCN1) is a secreted protein that is a target of the YAP/TAZ Hippo signalling molecules ([@bib84]; [@bib82]). CCN1 has been reported to mediate a variety of cellular processes, including adhesion, chemotaxis stimulation, survival, and angiogenesis, in a cell type-dependent manner ([@bib31]; [@bib56]). CCN1 also regulates the expression and activities of angiogenic factors, such as vascular endothelial growth factor (VEGF), in fibroblasts and osteoblasts ([@bib17]; [@bib37]; [@bib2]; [@bib22]). It is required for re-endothelialisation and wound repair in contexts where angiogenesis is indispensable ([@bib2]; [@bib5]). The angiogenic behaviour of CCN1 has been attributed to its binding to integrin αvβ3, a major integrin expressed in ECs ([@bib54]). *Ccn1*-null mice suffer embryonic lethality due to insufficient placental and embryonic blood vessel integrity ([@bib4]), and *Ccn1*-knockdown in mouse embryos causes atrioventricular valve and septal defects due to apoptosis in the cushion tissue and reduction in gelatinase activity ([@bib61]); this phenotype overlaps with VEGF-knockout phenotypes in the cardiovascular system ([@bib23]). However, CCN1 is not expressed much in ECs but is rather expressed in other parenchymal or mesenchymal cells ([@bib74]), and thus, an EC-specific knockout strategy is likely not suitable for identification of the role of CCN1 in sprouting angiogenesis.

YAP/TAZ are overexpressed in various cancer tissues and have been identified as prognostic markers ([@bib77]; [@bib34]). Immunohistochemistry (IHC) of tumours has revealed prominent expression and nuclear localization of YAP/TAZ in correlation with malignant features and poor patient outcomes ([@bib83]). *CCN1* is a well-known transcriptional target of YAP/TAZ ([@bib85]), is secreted in cancer cells, and induces extensive tumour angiogenesis, underscoring its paracrine angiogenic effect ([@bib35]; [@bib57]). Thus, targeting abnormally activated YAP/TAZ is a promising strategy for the suppression of tumour progression, metastasis, and cancer relapse ([@bib21]; [@bib79]). In addition, activation of YAP/TAZ by VEGF, a known angiogenic factor, facilitates expression of CCN1 ([@bib78]). The presence of YAP in embryonic retinal vessels, along with reduced retinal vascular sprouting and decreased numbers of vascular branches upon EC-specific deletion of embryonic YAP/TAZ, has further emphasised the importance of YAP/TAZ in vascular development ([@bib20]; [@bib69]).

Three types of functionally different ECs participate in the angiogenic process: tip cells, stalk cells, and phalanx cells ([@bib25]). All of these are engaged in the processes of vascular maturation and the maintenance of vascular integrity, thereby optimising blood flow, tissue perfusion, and oxygenation ([@bib25]). Tip cells are characterised by their position at the very tops of angiogenic sprouts and have extensive filopodial protrusions directed toward angiogenic attractants. Tip cells have a specific molecular signature, characterised by the expression of vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR3, and DLL4. It has been reported that the VEGF gradient is important in the selection and induction of endothelial tip cells. Binding of VEGFR2 induces a signalling cascade that enables the activation of Notch-Delta signalling via DLL4 expression in ECs, converting them into tip cells; however, mechanism of sustained tip cell activity other than VEGF-mediated signalling has not yet been elucidated.

Here, we report that CCN1 plays crucial role as an auto-inducer of tip cell fate that stimulate angiogenesis through the interplay of YAP/TAZ signalling with the integration of integrin αvβ3-VEGFR2, suggesting a promising approach for the treatment of pathological angiogenesis facilitated by extensive stimulation of tip cells.

Results {#s2}
=======

CCN1 promotes sprouting angiogenesis in zebrafish {#s2-1}
-------------------------------------------------

Secreted CCN1 is reported to facilitate EC migration and tumour angiogenesis via a paracrine effect ([@bib35]; [@bib57]), and YAP, an upstream regulator of CCN1, is expressed in the developing front of mouse retinal vessels ([@bib19]). Thus, to examine the precise mechanistic involvement of CCN1 in vascular formation, we designed two kinds of morpholino (MO) to target the transcription start site (ATG MO) or intron 1/exon 2 boundary of the *ccn1* gene (Splicing MO) ([Figure 1A](#fig1){ref-type="fig"}) and observed vascular development in TG (*flk1:EGFP*) embryos. MO-mediated knockdown of *ccn1* caused the formation of small heads, oedema, and bent trunk regions ([Figure 1B](#fig1){ref-type="fig"}). In TG (*flk1:EGFP*) embryos, control MO injection resulted in the formation of T-shaped intersegmental vessels (ISVs) and dorsolateral anastomose vessels (DLAVs) at 40 hr post-fertilisation (hpf) (I′ and II′ in [Figure 1B](#fig1){ref-type="fig"}), whereas the vasculature in the head and trunk regions of *ccn1* morphants was abnormally sprouted and disconnected (III′, IV′, V′, and VI′ in [Figure 1B](#fig1){ref-type="fig"}). *ccn1* morphants lost the T-shaped morphology previously displayed at the DLAV and ISV connexions (IV′ and VI′ in [Figure 1B](#fig1){ref-type="fig"}). When we observed more precisely in ISVs, in control animals, frontal cells from the DA migrated along a left-ascending path to the parachordal vessel (PAV) and then along a right-ascending path to the DLAV (I and II, arrows in [Figure 1B](#fig1){ref-type="fig"}); conversely, in two kinds of *ccn1* morphants, these cells took a right and then left-ascending or bifurcating path to DLAV or not migrating from DAV (III-VI, arrows in [Figure 1C](#fig1){ref-type="fig"}, [Figure 1D](#fig1){ref-type="fig"}), and disconnected or malformed DLAV (III-VI arrowheads in [Figure 1C](#fig1){ref-type="fig"}, [Figure 1D](#fig1){ref-type="fig"}) were significantly increased at both 32 and 40 hpf. However, injection of sense RNA of *ccn1* significantly rescued the vascular malformations and altered phenotypes induced by *ccn1* morpholinos ([Figure 1C](#fig1){ref-type="fig"} VII and VIII), suggesting that CCN1 is an essential factor for the vascular development in zebrafish. In addition, *ccn1* morphants demonstrated ectopic expression of *flk-1,* which was expressed not in vascular ECs but across the entire anterior--posterior body axis ([Figure 1E](#fig1){ref-type="fig"}). Aortic vessels disappeared and changed into venous types as detected by in situ expression of *Notch-1b* (aortic marker) and *Flt-4* (venous marker) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Therefore, the results suggest that CCN1 is essential for the normal migration and sprouting as well as the identity of ECs in zebrafish vascular development.

![CCN1 knockdown induces defects in vessel migration and sprouting as well as identity of endothelial cells in zebrafish vascular development.\
(**A**) Scheme showing *ccn1* gene exon and intron. Morpholinos (MO) binding to *ccn1* ATG starting site (ATG MO) and intron 1/exon two boundary region (Splicing MO) denoted as red lines were synthesised and injected into one-cell-stage zebrafish embryos. (**B**) Lateral view of Tg(*Flk;EGFP*) embryos in head and trunk regions of control (I--II for bright field, I′--II′ for dark field) and *ccn1* morphants (MO) (III--VI for bright field, III′--VI′ for dark field) at 40 hpf. Arrows indicates sprouting vessels. Arrows indicate dorsolateral anastomose vessels (DLAV), intersegmental vessels (ISV), parachordal vessel (PAV), dorsal aorta (DA) and pericardial vein (PCV). The white square was enlarged and placed next to it. Scale bar = 25 µm (**C**) Anterior regions in trunk vessels were magnified at 32 and 40 hpf, in control, *ccn1* MO-treated (III-VI) and *ccn1* RNA rescued (VII-VIII) embryos. Arrows indicate misdirected or disconnected vessels and arrowheads do disconnected or abnormal DLAV. Scale bar = 50 µm. (**D**) Number of intersomitic vessel (ISV) defect were counted in each embryo and graphed. (**F**) Whole mount in situ hybridization was performed with control and *ccn1* MO embryos at 24 hpf and 32 hpf with *zFlk1* antisense probe. Purple colour shows expression of *zFlk1* mRNA expression. Arrows indicates ISVs. Scale bar = 100 µm.](elife-46012-fig1){#fig1}

CCN1 promotes endothelial sprouting activity in angiogenesis {#s2-2}
------------------------------------------------------------

CCN1 is expressed during active angiogenic stages in postnatal retina tip cells, and its expression decreases upon EC maturation ([@bib19]). However, the above experiment raised the question of why CCN1 deletion increases sprouting and whether CCN1 can stimulate or inhibit tip cell activity. We used recombinant CCN1 protein to mimic the secreted protein ex vivo and performed a mouse aortic ring assay, as well as an EC spheroid sprouting assay in vitro, using VEGF-A (VEGF) as a positive control. CCN1 induced intensive vascular sprouts from aortic explants and significantly increased tip cell populations to the same degree as VEGF, as determined by tip cell markers, DLL4 and CD34 ([@bib72]) as well as an EC marker, CD31 ([Figure 2A](#fig2){ref-type="fig"}). CCN1 also significantly increased sprouting branches from spheroids, as determined by both lengths and numbers of tip cells after immunostained with DLL4 and CD34 antibodies ([Figure 2B](#fig2){ref-type="fig"}). Filopodial formation, which is an important marker of tip cells in migrating cells, was also detected in vitro by immunostaining with phalloidin. In human ECs, filopodia markedly increased upon exposure to CCN1 ([Figure 2C](#fig2){ref-type="fig"}). To investigate the angiogenic activity of CCN1, we performed in vitro angiogenesis, tube formation, and EC migration assays. CCN1 markedly increased capillary tube formation ([Figure 2D](#fig2){ref-type="fig"}) and promoted EC migration in the wound migration assay ([Figure 2E](#fig2){ref-type="fig"}, [Videos 1](#video1){ref-type="video"} and [2](#video2){ref-type="video"}). Because tip and stalk cell activities are increased during active angiogenesis ([@bib25]), we checked whether the expression of marker genes for tip and stalk cells changed following CCN1 treatment in human umbilical vein ECs (HUVECs). Expression levels of tip cell marker genes like *VEGFR2, DLL4* ([@bib36]), and *SOX17* ([@bib53]) were elevated, but those of stalk cell marker genes like *JAG1, ROBO4,* and *NOTCH1* were not changed by CCN1, nor by VEGF ([Figure 2F](#fig2){ref-type="fig"}). Protein levels of VEGFR2, DLL4, and SOX17 were also increased by CCN1 ([Figure 2G](#fig2){ref-type="fig"}). To confirm these results, *DLL4* promoter-driven luciferase (*DLL4-Luc*) reporter activity was observed. *DLL4-Luc* reporter activity was significantly increased by CCN1, as by VEGF ([Figure 2H](#fig2){ref-type="fig"}). These results clearly suggest that CCN1 induces tip cell activity and identity in sprouting during angiogenesis.

![CCN1 stimulates tip cell activity in ECs.\
(**A**) Mouse aorta isolated and cut at 6 weeks old, planted on Matrigel-coated plate and incubated for 7 days in presence or absence of CCN1 (10 ng/mL) or VEGF (10 ng/mL). Expression of CD31, DLL4, and CD34 were visualised with respective antibodies by the immunofluorescent assay under the confocal microscope. Tip cells expressing CD31+/DLL4+/CD34+ cells were counted and graphed. Three independent experiments were performed (n = 3/group). \*p\<0.05 vs control. Scale bar = 100 µm. (**B**) HUVEC spheroids were cultured in presence or absence of CCN1 (10 ng/mL) or VEGF (10 ng/mL) for 48 hr. Expression of CD31, DLL4, and CD34 were visualised with respective antibodies by the immunofluorescent assay under the confocal microscope. Length of sprout and tip cells expressing CD31+/DLL4+/CD34+ cells were counted and graphed (n = 3/group). \*\*p\<0.01 vs Control. Scale bar = 100 µm. (**C**) Filopodia number per field was counted in HUVEC cells treated with PBS (Control) or CCN1 (10 ng/mL) for 30 min and imaged using confocal microscope after staining with vinculin (red) and phalloidin (green). \*p\<0.0001 vs. Control. Scale bar = 25 µm. (**D**) Branching points of tubular networks were counted in HUVECs cultured in the presence or absence of CCN1 or VEGF for 48 hr (n = 3/group). Magnification = 40 × . \*p\<0.05 vs. control. (**E**) Confluent HUVECs were wounded and cultured in the presence or absence of CCN1 or VEGF for 6 hr. Migrating cells from wound line (dotted line) were counted (n = 3/group). Magnification = 40 × . \*p\<0.05 vs. control. (**F**) HUVECs were treated with CCN1 (10 ng/mL) or VEGF (10 ng/mL) for 24 hr, and total RNA was collected for real-time qRT-PCR analysis. Expression of tip cell marker genes (*SOX17, DLL4, VEGFR2*) and stalk cell marker genes (*JAG1, NOTCH1, ROBO4*) was analyzed. \*p\<0.05 or \*\*p\<0.01 vs. Control. (**G**) Western blotting analysis of VEGFR2, DLL4, and SOX17 protein levels in the same samples as used in **F**. β-actin was used as an internal control. Fold increase was indicated as a number below each band. (**H**) Luciferase assays in HUVECs transfected with *DLL4-Luc* reporter vector and treated with CCN1 or VEGF (10 ng/mL) for 24 hr. Luciferase activity was normalised to *Renilla* luminescence. \*p\<0.001 vs. Control.\
10.7554/eLife.46012.005Figure 2---source data 1.Source data for [Figure 2G](#fig2){ref-type="fig"}.](elife-46012-fig2){#fig2}

###### CCN1 promoted EC migration.

10.7554/eLife.46012.006

###### CCN1 promoted EC migration.

10.7554/eLife.46012.007

CCN1-induced YAP/TAZ activation via VEGFR2 signalling is critical for tip cell activity {#s2-3}
---------------------------------------------------------------------------------------

YAP/TAZ have critical roles in vascular sprouting ([@bib41]; [@bib65]), and their activation promotes tip cell activity and expression of target genes, such as *Ccn1* ([@bib69]). Thus, the probable involvement of VEGFR2 signalling in the regulation of YAP/TAZ was investigated in CCN1-treated ECs. YAP and TAZ translocation to the nucleus was significantly upregulated by treatment with CCN1 for 1 hr in a dose-dependent manner ([Figure 3A](#fig3){ref-type="fig"}). Phosphorylation of YAP/TAZ at S127/89, respectively, leads to cytosolic degradation, thus inhibiting their nuclear localization. In growth factor-mediated YAP signalling via the MAPK and PI3K nexus, large tumour suppressor kinase 1 (LATS1), a tumour suppressor that phosphorylates YAP/TAZ, is repressed through reduced phosphorylation, thus enhancing the nuclear localization of YAP ([@bib32]; [@bib42]). We found that levels of phosphorylated LATS were decreased maximally at 1 hr and those of phosphorylated YAP/TAZ were decreased from 15 min, maximally at 1 hr by CCN1 in HUVECs ([Figure 3B](#fig3){ref-type="fig"}), indicating that CCN1 activates YAP/TAZ in ECs at the early time after stimulation.

![CCN1-VEGFR2-MAPK, PI3K-YAP/TAZ signalling involved in CCN1-mediated tip cell activation.\
(**A**) Nuclear localization of YAP/TAZ in HUVECs treated with CCN1 at 5, 10, or 50 ng/mL for 1 hr. (**B**) Western blotting of LATS, YAP, and TAZ and their phosphorylated forms in HUVECs treated with CCN1 (10 ng/mL) for indicated times. Quantitation for phosphorylated protein level was normalised by each protein and graphed shown in right panel. \*p\<0.05 vs. Control. (**C**) Western blotting of phosphorylated VEGFR2 at tyrosine (Y)−1054/1059 and Y1175 in HUVECs treated with VEGF (10 ng/mL) or CCN1 (10 ng/mL) for 5, 10, 15, 30, or 60 min. β--actin was used as a loading control. (**D**) Western blotting of VEGFR2 phosphorylated at Y1054/1059 and Y1175 in HUVECs treated with VEGF (10 ng/mL) or CCN1 (0, 1, 5, or 10 ng/mL) for 30 min. β--actin was used as a loading control. (**E**) Western blotting of VEGFR2 phosphorylated at Y1054/1059 and Y1175 in HUVECs transfected with *CCN1* siRNA. β--actin was used as a loading control. (**F**) Western blotting of phosphorylated or natural forms of p-ERK, p38 MAPK, and p85 PI3K in HUVECs were treated with VEGF or CCN1 (10 ng/mL) for 15 min. (**G, H**) *DLL4* mRNA (**G**) and protein (**H**) levels in EA.hy926 cells treated with PBS (Control) or CCN1 (10 ng/mL) alone or together with MAPK kinase inhibitors PD98059, SP600125, or SB203580 (20 mM) or PI3K inhibitor LY294002 (20 mM) for 24 hr. \*p\<0.005 vs. Control, ^\#^p\<0.0001 vs. CCN1. (**I**) Filopodia number per field was quantified after staining with anti-vinculin antibody (red) and phalloidin (green) in EA.hy926 cells treated with PBS (Control) or CCN1 (10 ng/mL) alone or together with PD98059 (20 mM), SP600125 (20 mM), SB203580 (20 mM), or LY294002 (20 mM) for 30 min. Scale bar = 10 µm. \*p\<0.0001 vs. Control, ^\#^p\<0.0001 vs. CCN1. (**J**) Western blotting of indicated proteins in EA.hy926 cells treated with PBS (Control) or CCN1 (10 ng/mL) alone or together with PD98059 (20 mM), SB203580 (20 mM), or LY294002 (20 mM) for 1 hr. (**K**) *CCN1* mRNA expression determined by qRT-PCR of total RNA obtained from the same groups as in **G** but treated with CCN1 for 24 hr. \*p\<0.005 vs. Control, ^\#^p\<0.005 vs. CCN1. (**L**) Detection of DLL4, VEGFR, and CCN1 proteins in HUVECs treated with CCN1 (10 ng/mL) for 24 hr in the presence or absence of verteporfin (VP, 100 nM) for 24 hr. Fold changes were noted under each protein band in C-F, H, J and L.\
10.7554/eLife.46012.010Figure 3---source data 1.Source data for [Figure 3B, C, D, E, F, H, J, L](#fig3){ref-type="fig"}.](elife-46012-fig3){#fig3}

VEGFR2 signalling is reportedly linked to YAP/TAZ activation in developmental angiogenesis ([@bib78]). VEGFR2 activation is a key event in determining the fate of an EC as a tip cell ([@bib16]). Thus, we investigated whether VEGFR2 is activated by CCN1 in ECs. CCN1 induced the phosphorylation of VEGFR2 from 10 min at slightly earlier time point of YAP/TAZ activation within 1 hr ([Figure 3C](#fig3){ref-type="fig"}) and in a dose-dependent manner ([Figure 3D](#fig3){ref-type="fig"}). VEGFR2 activation after serum stimulation ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) ([@bib51]) was highly repressed upon siRNA-mediated *CCN1* knockdown (siCCN1) ([Figure 3E](#fig3){ref-type="fig"}), suggesting that CCN1 activates VEGFR2. To confirm whether CCN1 is able to activate VEGFR2 in the absence of endogenous VEGF, we transfected HUVECs with siVEGF and found that CCN1 activated VEGFR2 regardless of endogenous VEGF ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Knockdown of *CCN1* with siCCN1 repressed the mRNA expression of the tip cells markers, *DLL4* and *VEGFR2* ([Figure 2](#fig2){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}) as well as the migration and sprouting ability ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), indicating that endothelial CCN1 is important for EC tip cell activity. The phosphorylation of Y1054/1059 in the VEGFR2 kinase domain mediates kinase activity, and that of Y1175 mediates binding to the p85 subunit of PI3K and to MAPKs, which is involved in migration as well as proliferation ([@bib64]). Recently, it has been reported that VEGFR activation induces downstream kinases to inhibit LATS function and activate YAP/TAZ ([@bib3]). Therefore, we checked that extracellular signal-regulated kinase (ERK), p38 MAPK, and p85 PI3K, all downstream targets of Y1175 phosphorylation, were activated by CCN1 ([Figure 3F](#fig3){ref-type="fig"}). Next, to confirm whether CCN1-mediated tip cell activity involves the MAPK and PI3K signalling cascades, we used pharmacological inhibitors for ERK1/2 (PD98059), p38 MAPK (SB203580), JNK MAPK (SP600125), and PI3K (LY294002). Upon treatment with all inhibitors except SP600125, *DLL4* mRNA and protein levels were highly repressed ([Figure 3G and H](#fig3){ref-type="fig"}). To confirm these results, filopodial formation, as determined by phalloidin staining, was highly reduced in ECs exposed to CCN1 together with the inhibitors ([Figure 3I](#fig3){ref-type="fig"}). CCN1-mediated increases in the phosphorylation of STAT-1 and STAT-3 further implicate its probable involvement in VEGFR2 activation, similar to that of VEGF ([@bib7]; [@bib8]) ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). Thus, collectively, these results suggest that CCN1 induces tip cell activation through the VEGFR2/ERK1/2 and p38MAPK/PI3K signalling pathways in ECs.

Next, we determined whether the CCN1-induced MAPK and PI3K signalling pathways are involved in the activation of YAP/TAZ. The phosphorylation of LATS1 and YAP/TAZ was decreased by CCN1, but the PD98059, SB203580, and LY294002 inhibitors restored phosphorylation to control levels, thus confirming the repression of phosphorylated LATS1 in ECs, resulting in YAP/TAZ activation by CCN1 ([Figure 3J](#fig3){ref-type="fig"}). In support of these findings, expression of YAP/TAZ target gene *CCN1* was also significantly increased by CCN1 treatment and repressed by PD98059, SB203580, and LY294002 ([Figure 3K](#fig3){ref-type="fig"}), suggesting the involvement of MAPK and PI3K as well as the expression of CCN1 via the activation of YAP/TAZ in ECs. An inhibitor of YAP/TAZ, verteporfin (VP), inhibited VEGFR2, CCN1, and DLL4 expression induced by CCN1, confirming the involvement of YAP/TAZ in tip cell activity ([Figure 3L](#fig3){ref-type="fig"}). These results suggest that CCN1 activates the VEGFR2-MAPK/PI3K-YAP/TAZ pathway to facilitate the turnover of CCN1, further sustaining tip cell activity in ECs.

mDia1 is involved in CCN1-induced filopodial formation and YAP/TAZ activation in ECs {#s2-4}
------------------------------------------------------------------------------------

Polymerization of actin and the fast-growing end of actin filaments is a crucial step in filopodial formation, and mDia1, a formin family protein, is essential for Rho GTPase-induced filopodial formation ([@bib26]; [@bib27]). Therefore, we investigated whether mDia1 is involved in CCN1-induced filopodial formation in ECs. We found that CCN1 increased *DIAPH1* mRNA expression by 1.5-fold ([Figure 4A](#fig4){ref-type="fig"}) and also overexpression of *DIAPH1 (mDia1)* increased filopodial numbers similar to that in CCN1-treated HUVECs ([Figure 4B](#fig4){ref-type="fig"}). However, *DIAPH1* dominant-negative mutation decreased CCN1-induced filopodial formation ([Figure 4B](#fig4){ref-type="fig"}), suggesting that mDia1 is essential for CCN1-induced filopodial formation in ECs. Since the small Rho GTPase Cdc42 is critical for EC motility by promoting endothelial focal adhesions and filopodial formation by regulating actomyosin contractility ([@bib6]) and tip cell migration ([@bib69]), we assessed levels of activated Cdc42 GTPases. The active form of Cdc42 assayed by pull-down and immunoprecipitation (IP) analysis as described previously ([@bib76]) was increased by CCN1 treatment and *DIAPH1* overexpression but not the *DIAPH1* mutant with CCN1 ([Figure 4C](#fig4){ref-type="fig"}). Phosphorylated N-Wasp, induced by active Cdc42 ([@bib69]), was also detected in CCN1-treated and *DIAPH1*-overexpressing cells but not in *DIAPH1* mutant-expressing cells ([Figure 4D](#fig4){ref-type="fig"}), suggesting that mDia1 is required for CCN1-induced Cdc42 activation in tip cell formation. Next, we further identified whether CCN1-induced mDia1 activation is responsible for the YAP/TAZ activation. Nuclear localization of YAP/TAZ was induced by overexpression of *DIAPH1* as well as CCN1 treatment, but not by the *DIAPH1* DN mutants ([Figure 4E](#fig4){ref-type="fig"}), indicating that mDia1 is necessary for YAP/TAZ nuclear translocation in CCN1-induced tip cell formation.

![mDia1is essential for CCN1-induced Cdc42 activation in tip cell formation.\
(**A**) HUVECs were treated with PBS (Control) or CCN1 (10 ng/mL) for 24 hr, and total RNA was used for the detection of *DIAPH1 (mDia1)* mRNA expression by qRT-PCR. \*p\<0.001 vs. Control. (**B**) After transfection with *DIAPH1* WT full length and *DIAPH1* double-negative mutant plasmids, HUVECs were treated with CCN1 and immunostained with anti-vinculin antibody (red) and phalloidin (green) to visualise filopodia. Scale bar = 10 µm. (**C, D**) HUVECs transfected with *DIAPH1* WT full length and *DIAPH1* double-negative mutant plasmids were treated with CCN1 (10 ng/mL) for 30 min, and active Cdc42 was assessed by western blotting analysis (**C**) and visualised by p-N-Wasp (**D**). Fold changes were noted under each protein band. (**E**) After HUVECs were transfected with *DIAPH1* WT full length and *DIAPH1* DN3 mutant plasmid, starved cells for 16 hr were treated with CCN1 10 ng/ml for 1 hr and detected YAP/TAZ by IF. Scale bar = 100 µm.\
10.7554/eLife.46012.012Figure 4---source data 1.Source data for [Figure 4C](#fig4){ref-type="fig"}.](elife-46012-fig4){#fig4}

Integrin αvβ3 is a key mediator of hippo pathway induced by CCN1 {#s2-5}
----------------------------------------------------------------

Integrins involved in various functions, are induced by CCN1, and are also reported to activate VEGFR2 and its downstream signalling pathway ([@bib18]). Integrins αvβ3 and αvβ1 are involved in EC migration induced by CCN1 ([@bib18]) and are the major vitronectin receptors on ECs. As the ability of ECs to adhere to vitronectin in the presence of CCN1 was completely blocked by the addition of β3 antibody at 45 min ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}), αvβ3 may be the major receptor mediating adhesion of CCN1 to ECs ([@bib45]). We also found that integrin β1 was not involved in the adhesion of fibronectin to ECs ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). To confirm whether integrin αvβ3 is essential for the induction of tip cells by CCN1, we first checked whether CCN1 regulates integrin β3 expression. CCN1, as well as VEGF increased β3 integrin expression according to western blotting (WB) and immunofluorescence (IF) assays ([Figure 5---figure supplement 1B,C](#fig5s1){ref-type="fig"}), suggesting autocrine regulation of CCN1 angiogenic signalling through integrin αvβ3.

Next, to gain insight into the molecular involvement of integrin αvβ3 in CCN1-induced tip cell activity, we investigated whether integrin αvβ3 interacts with VEGFR2 via CCN1. IP and WB analyses showed strong interactions between VEGFR2 and integrin αvβ3, as well as their interaction with CCN1 upon CCN1 treatment for 24 hr. However, cell exposure to the αvβ3 inhibitor peptide cyclo(RGDfK) blocked the interactions of VEGFR2 with integrin αvβ3, CCN1 with integrin αvβ3, and CCN1 with VEGFR2 ([Figure 5A](#fig5){ref-type="fig"}). In addition, in situ proximity ligation assay (PLA) also clearly revealed increased interactions among CCN1/integrin αvβ3/VEGFR2 in ECs compared to that in controls ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). CCN1-induced VEGFR2 downstream kinase signalling activity was inhibited by cyclo(RGDfK) ([Figure 5C](#fig5){ref-type="fig"}). We also determined whether integrin αvβ3 is essential for YAP/TAZ activation by CCN1. Co-treatment with cyclo(RGDfK) rescued the decreased phosphorylation of YAP/TAZ by CCN1 ([Figure 5D](#fig5){ref-type="fig"}). At the same time, increased YAP/TAZ nuclear localization in the CCN1-treated group was blocked by cyclo(RGDfK) co-treatment ([Figure 5E](#fig5){ref-type="fig"}), followed by repressed *DLL4-Luc* activity and expression of tip cell marker genes *DLL4* and *SOX17* ([Figure 5F and G](#fig5){ref-type="fig"}). These results suggest that CCN1-mediated tip cell activation is regulated by YAP/TAZ through the integrin αvβ3/VEGFR2 signalling pathway.

![Tip cell properties are induced by CCN1 via interactions between integrin αvβ3 and VEGFR2.\
(**A**) HUVECs treated with CCN1 (10 ng/mL) for 24 hr in the presence or absence of cyclo(RGDfK) (1 μg/mL) were used for IP and immunoblotting analyses to detect interactions between integrin αvβ3 and VEGFR2 or Cy61. β-actin was used as an internal loading control. (**B**) Proximity ligation assay was performed, and double-fluorescent microscopic images showing protein--protein interactions in cells were quantified. \*p\<0.01, \*\*p\<0.05 vs. Control, ^\#^p\<0.01 vs. CCN1. (**C, D**) HUVECs were treated with CCN1 (10 ng/mL) for 30 min (**C**) or 1 hr (**D**) in the presence or absence of cyclo(RGDfK) (1 µg/mL), and western blotting was performed for the indicated proteins. Fold changes were noted under each protein band. (**E**) The same samples as in D were analysed for the nuclear localization of YAP/TAZ via IF. \*p\<0.05 vs. Control, ^\#^p\<0.05 vs. CCN1. (**F**) HUVECs were transfected with *DLL4-Luc* reporter vector and treated with CCN1 (10 ng/mL) for 24 hr in the presence or absence of cyclo(RGDfK) (1 μg/mL). Luciferase activity was normalised to *Renilla* luminescence. \*p\<0.01 vs. Control, ^\#^p\<0.01 vs. CCN1. (**G**) Total RNA was obtained from HUVECs treated with CCN1 (10 ng/mL) for 24 hr in the presence or absence of cyclo(RGDfK) (1 μg/mL). Expression levels of *DLL4* and *SOX17* mRNA were determined by qRT-PCR. \*p\<0.01, \*\*p\<0.05 vs. Control, ^\#^p\<0.01 vs. CCN1. (**H**) Aortic sprouting assays were performed and determined after incubation with CCN1 (10 ng/mL) in the presence or absence of cyclo(RGDfK) for 7 days. Expression of CD31, DLL4, and CD34 were visualised with their antibodies by the immunofluorescent assay under the confocal microscope. Tip cells expressing CD31+/DLL4+/CD34+ cells were counted and graphed. Three independent experiments were performed (n = 3/group). \*p\<0.05 vs control. Scale bar = 100 µm. (**I**) Spheroid assays were performed with CCN1 (10 ng/mL) in the presence or absence of cyclo(RGDfK) for 48 hr. Expression of CD31, DLL4, and CD34 were visualised with their antibodies by the immunofluorescent assay under the confocal microscope. Length of sprout and tip cells expressing CD31+/DLL4+/CD34+ cells were counted and graphed (n = 3/group). Scale bar = 100 µm \*\*p\<0.001 vs. Control, ^\#^p\<0.05 vs. CCN1 only.\
10.7554/eLife.46012.015Figure 5---source data 1.Source data for [Figure 5C and D](#fig5){ref-type="fig"}.](elife-46012-fig5){#fig5}

We then repeated the aortic ring and EC spheroid sprouting assays in the presence of cyclo(RGDfK). In aortas treated with cyclo(RGDfK), CCN1-induced tip cell numbers were significantly decreased CD31+/DLL4+/CD34+ tip cells in [Figure 5H](#fig5){ref-type="fig"}. CCN1 increased the sprouting length and tip cell number by 2- and 3.5-fold, respectively, when compared to control group, and this was abolished by cyclo(RGDfK) in cultured spheroids ([Figure 5I](#fig5){ref-type="fig"}).

Endothelial CCN1 via integrin αvβ3 is crucial for vascular sprouting and growth in vivo. {#s2-6}
----------------------------------------------------------------------------------------

Because *Ccn1* mRNA expression is much lower in ECs than in other mesenchymal cells or some epithelial cells ([@bib74]) but *Ccn1* mRNA is expressed in the front region of developing retinal vessels, to investigate the role of CCN1 in ECs in vivo, we generated EC-specific TG mice rather than knockout mice. Visualisation of developing vessels by IF staining with isolectin B4 and CCN1 antibodies revealed that CCN1 was not highly expressed in retinal ECs at postnatal day 6 (P6) ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) ([@bib19]). In EC-specific *Ccn1*-TG mice, we confirmed that CCN1 was expressed in retinal ECs ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), together with significant increases in retinal vessel branching and number of tip cells with filopodia ([Figure 6A,B](#fig6){ref-type="fig"}). However, in each retinal quadrant, the radial outgrowth of retinal vessels from the optic nerve head to the peripheral vascular front was similar to that observed in wild-type (WT) mice ([Figure 6A](#fig6){ref-type="fig"}), indicating a specific role for CCN1 in endothelial branching and tip cell formation in vivo. Following injection of cyclo(RGDfK) for 2 days, the number of sprouting tip cells with filopodia significantly decreased at P5 and P6 ([Figure 6B](#fig6){ref-type="fig"}). To further investigate the autoregulation of CCN1 in sprouting angiogenesis in vivo, we performed aortic ring and Matrigel invasion assays in *Ccn1*-TG mice. The aortic rings isolated from these TG mice showed an increased number of tip cells and sprouting ECs compared to those in WT mice, and these were significantly reduced in cyclo(RGDfK)-treated aortas ([Figure 6C](#fig6){ref-type="fig"}). In addition, cyclo(RGDfK) treatment repressed in vivo angiogenesis in the Matrigel plug assay. Haematoxylin and eosin (H and E) staining of sections of plugs from *Ccn1*-TG mice revealed an increased number of neovessels and microvessels compared to that in controls, while in Matrigel plugs treated with cyclo(RGDfK), both neovessel and microvessel densities were decreased compared to those in *Ccn1*-TG mice without cyclo(RGDfK) ([Figure 6D](#fig6){ref-type="fig"}). Similar results were observed in the CAM assay, with results of treatment with CCN1 alone or together with cyclo(RGDfK) further strengthening the above finding ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). We also confirmed that treatment with SU5416, a VEGFR2 kinase-specific inhibitor, demonstrated the same inhibitory results in CAM and Matrigel plug assays following treatment with CCN1 ([Figure 6---figure supplement 2A,B](#fig6s2){ref-type="fig"}). To rule out endogenous VEGF as a prime effector of angiogenesis in *Ccn1*-TG mice, we compared the plasma VEGF levels of the WT and TG mice. Levels of plasma VEGF did not differ between WT and EC-specific *Ccn1*-TG mice, and treatment of cultured ECs with CCN1 did not affect secreted VEGF levels ([Figure 6---figure supplement 2C,D](#fig6s2){ref-type="fig"}). Therefore, collectively, these results indicate that integrin αvβ3 and VEGFR2 are involved in CCN1-induced tip cell generation and sprouting during in vivo angiogenesis. Finally, we confirmed the expression patterns of VEGFR2 and integrin β3 in the mice. In *Ccn1*-TG mice, we observed significantly increased and co-localised expression of VEGFR2 and integrin β3 in the front region of the retinal vessels ([Figure 6E](#fig6){ref-type="fig"}). Taken together, these data indicate that CCN1 induces ECs to acquire tip cell activity via the activation of VEGFR2 signalling through integrin αvβ3.

![Endothelial CCN1 is crucial for sprouting angiogenesis.\
(**A, B**) Whole mount retinas at postnatal day 5 (P5) stained with anti-IB4 antibody, allowing comparison of whole retina (upper) and peripheral retina ECs (lower) in WT and TG mice. Yellow dots represent sprouting tip cells. Tip cell number was counted and shown in B. Scale bar = 50 μm (upper) and 100 μm (lower). \*p*\<*0.001, \*\*p*\<*0.01. (**C**) Mouse aortas from WT and *Ccn1*-TG mice were plated on Matrigel-coated plates and treated with cyclo(RGDfK) (1 μg/mL). Tip cells among sprouting ECs were counted and graphed. Three independent experiments were performed (n = 3/group). Magnification = 5 × . (**D**) Matrigel was inoculated into flanks of WT or *Ccn1*-TG mice and treated with cyclo(RGDfK) (20 mg/kg). After 7 days, Matrigel plugs were isolated, sectioned, and stained with H and E. Magnification = 400 × . Scale bar = 100 μm. Vessel density was quantified and graphed. \*p\<0.001 vs. Control, \*\*p\<0.01 vs. TG. (**E**) Expression of integrin β3 and VEGFR2 was determined via immunofluorescence and quantified in P5 retinas of WT and *Ccn1*-TG mice. Scale bar = 50 μm. \*\*\*p\<0.001, \*p\<0.05 vs. Control.](elife-46012-fig6){#fig6}

Role of CCN1 in pathological angiogenesis and clinical correlation with integrin/Hippo pathway {#s2-7}
----------------------------------------------------------------------------------------------

YAP/TAZ are overexpressed in various cancer tissues, and their nuclear localization has been identified as a potential prognostic marker ([@bib77]; [@bib34]; [@bib83]). To address the role of CCN1 in pathological angiogenesis, we used an allograft Lewis lung carcinoma (LLC) tumour model in EC-specific *Ccn1*-TG mice. Surprisingly, induced expression of *Ccn1* in ECs induced active angiogenic vessels, representing a significant decrease in pericyte coverage, both in the central and peripheral regions of the tumour ([Figure 7A](#fig7){ref-type="fig"}). *Ccn1* overexpression in ECs resulted in significant upregulation of VEGFR2 expression as well as increased sprouting activity in the central region of the tumour ([Figure 7B](#fig7){ref-type="fig"}). These results suggest that CCN1 induces active angiogenesis through VEGFR2 in pathological tumour vasculature.

![Role of CCN1 in pathological angiogenesis and clinical correlation with integrin/Hippo pathway.\
(**A**) LLC allograft tumour tissues in WT and *Ccn1*-EC-specific TG mice were extracted at 10 days after inoculation, sectioned, and immunostained with anti-CD31 and anti-PDGFβ antibodies and green and red fluorescently labelled secondary antibodies. Stained cells were quantified in the central and peripheral regions. Scale bar = 100 µm. \*p\<0.05, \*\*p\<0.01. (**B**) The same sectioned tissues as in (**A**) immunostained with anti-VEGFR2 and CD31. Quantitation was performed in the central and peripheral regions of the tissues. The number of sprouting sites was normalised to the total vessel length. Scale bar = 50 µm. \*p\<0.05, \*\*p\<0.01. (**C**) The difference in the survival curves of the two groups, *CCN1* high (red line) and *CCN1* low (blue line) 25% of patients with highest and lowest mRNA expression levels, respectively, n = 126/group\] was evaluated using log-rank test with Kaplan--Meier estimation. p=8.7 × 10^−3^ between two groups. (**D**) Box plots of normalised mRNA expression levels of *ITGB3, VEGFR2, DLL4, YAP*, and *WWTR1* in *CCN1*-high and *CCN1*-low groups.](elife-46012-fig7){#fig7}

Next, we investigated whether upregulated CCN1 expression is correlated with cancer patient survival and the expression of molecules involved in tip cell activity based on data from The Cancer Genome Atlas (TCGA). The overall survival rate was significantly higher in those with low expression of *CCN1* compared to that in the high expression group among lung squamous cell carcinoma (LUSC) ([Figure 7C](#fig7){ref-type="fig"}) as well as bladder urothelial cancer (BLCA) and stomach adenocarcinoma (STAD) patients ([Figure 7---figure supplement 1A,C](#fig7s1){ref-type="fig"}). In addition, we compared the expression of *ITGB3, VEGFR2, DLL4, YAP* and *WWTR1* in the *CCN1*-low and -high groups. *CCN1* expression was significantly positively correlated with *ITGB3, VEGFR2, DLL4, YAP* and *WWTR1* in LUSC ([Figure 7D](#fig7){ref-type="fig"}), BLCA, and STAD ([Figure 7---figure supplement 1B,D](#fig7s1){ref-type="fig"}). And the expression of angiogenic factors including VEGFR2 and Tie2 is significantly correlated with the expression of *CCN1* in these cancer patient cohorts ([Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). However, age showed no significant difference between *CCN1* high or *CCN1* low patient group in LUSC and STAD cohorts, whereas, in BLCA, age and stage of cancer showed significant (p\<0.05) difference or enrichment between *CCN1* high and *CCN1* low patient groups, suggesting potential association of age and stage of cancer with patient survival in BLCA ([Figure 7---figure supplement 1F--H](#fig7s1){ref-type="fig"}). Taken together, these results suggest that overexpression of YAP/TAZ increases CCN1 expression and secretion from cancer cells into the tumour microenvironment, which activates tip cell activity by increasing the expression of YAP/TAZ as well as VEGFR2 and DLL4 in ECs to promote vascular sprouting and tumour angiogenesis. Our results indicate that CCN1 expression induced by activated YAP/TAZ increases tip cell activity in ECs via filopodial formation mediated by the mDia1 Rho effector. CCN1 increases activation of the VEGFR2, ERK1/2, P38 MAPK, and PI3K signalling pathways by binding with integrin αvβ3 and VEGFR2. These signalling pathways subsequently induce YAP/TAZ activity and CCN1 expression, sustaining tip cell activity in ECs ([Figure 8](#fig8){ref-type="fig"}).

![Schematic diagram depicting CCN1 induction of tip cell identity through interplay of integrin αvβ3/VEGFR2 with Hippo pathway.\
CCN1 in the milieu is sensed by ECs by binding to membrane integrin αvβ3 and VEGFR2 receptors, thus activating the MAPK and PI3K-YAP/TAZ signalling pathways, leading to activation of YAP/TAZ. YAP/TAZ transfer to the nucleus facilitates transcriptional regulation of CCN1, which may sustain the CCN1-VEGFR2-MAPK, PI3K-YAP/TAZ signalling circuit for maintaining tip cell activity in ECs. In addition, CCN1-induced mDia1 is necessary for YAP/TAZ activation and leads to induce filopodia formation through increased Cdc42 Rho GTPase activity.](elife-46012-fig8){#fig8}

Discussion {#s3}
==========

Secretion of CCN1 by tumours can facilitate tumour angiogenesis ([@bib57]), and knockdown of *ccn1* in zebrafish resulted in defective vessels in terms of migration and development, especially sprouting behaviour. Based on these data, we attributed the angiogenic defects of CCN1 knockdown to the dysfunction of a specific type of EC: the tip cells. Tip cells migrate and branch according to increased concentrations of VEGF, whereas exposure to relatively low concentrations of VEGF induces the proliferation of stalk cells. Tip/stalk cell fate might be determined by different responses for cells to the environmental cue. It has been indicated that the main determinant for tip/stalk cell fate is the Notch signalling pathway ([@bib36]; [@bib10]; [@bib11]). Tip cell specification is initially achieved by DLL4 expression in the topmost cells and by Notch signalling in adjacent ECs. Tip cells that respond to VEGF signalling by increasing their levels of DLL4 expression have the strongest reactions to VEGF and acquire many filopodial phenotypes; in contrast, increased expression levels of Notch and Jagged-1 in neighbouring cells (stalk cells) suppress tip cell-like behaviour ([@bib16]). Increased expression of DLL4 is a key determinant for tip cell specification. DLL4/Notch1 signalling between adjacent ECs establishes an adequate ratio between tip cells and stalk cells in response to VEGF ([@bib36]). Here, we found that CCN1 increased tip cell phenotype and the expression of the tip cell marker gene *DLL4*, possibly mediated through the activation of VEGFR2 by CCN1. A new tip cell marker CD34 expressing ECs show low proliferation ([@bib72]), and CD34 has been expressed in undifferentiated cells with stem-cell properties, such as hematopoietic stem and progenitor cells ([@bib46]; [@bib63]), suggesting that tip cells rarely divide but have stem-like properties among ECs. CD34 expressed in sprouting aorta and spheroid ECs and CD34+/DLL4+ expressing ECs were increased by CCN1 treatment, confirming the CCN1-induced tip cell formation.

CCN1 is highly induced by hypoxia and is regulated via both hypoxia-inducible factor 1α (HIF-1α)-dependent and -independent mechanisms ([@bib49]; [@bib58]; [@bib80]). Since hypoxia enhances VEGF expression---in addition to regulating ECM composition, deposition, posttranslational modifications, and rearrangements ([@bib29])---it is possible that hypoxic conditions increase the formation of tip cells, followed by stalk cell proliferation and tube formation, to supply oxygen to cells through neovessels. Furthermore, hypoxia-induced CCN1 and VEGF can collaboratively activate tip cell induction in ECs. If branched vessels are formed, oxygenation lowers the levels of CCN1 or VEGF, resulting in the survival of quiescent phalanx cells ([@bib16]). It has been reported that CCN1 regulates the expression of VEGF-A and VEGF-C in fibroblasts ([@bib17]; [@bib60]). We did not observe increased levels of VEGF, either in the sera of EC-specific *Ccn1*-TG mice or in EC culture media treated with CCN1, which is consistent with previous results ([@bib19]). This discrepancy may be due to the EC-specific targeted effects. Therefore, these results suggest that CCN1 induces tip cell activity in ECs in the absence of VEGF through VEGFR2 activation and in collaboration with integrin αvβ3 ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Interestingly, during embryonic development, the expression patterns of VEGF and CCN1 almost overlap in the notochord, limbs, developing nervous system (including the ventral spinal cord, midbrain, and hair follicles), myocardium, truncus arteriosus, and dorsal aorta ([@bib24]; [@bib59]; [@bib51]; [@bib61]; [@bib47]). The expression of these proteins in certain mesenchymal and vascular regions, such as the dorsal aorta and placental vessels, overlaps with FLK1 (VEGFR2) expression ([@bib24]), suggesting that CCN1 may function in collaboration with VEGF and/or VEGFR2, depending on the cellular and developmental context.

During development, CCN1 is also widely expressed in the cardiovascular system ([@bib44]). Thus, CCN1-deficient mice provide some insight into the vital roles of CCN1 in cardiovascular development. The majority of *Ccn1-*null embryos die of haemorrhage and/or placental defects between E11.5 and E14.5 ([@bib60]). Moreover, vascular defects in chorioallantoic fusion---by under-vascularisation in the placental labyrinth or large vessel bifurcation---have been found in *Ccn1*-null embryos, along with dilated large foetal vessels, such as the aorta ([@bib60]). However, in P5 mice, the EC-specific deletion of CCN1 results in an increase in the number of tip cells in retinal ECs ([@bib19]). This result may reflect the high expression and secretion of CCN1 in other cell types, increasing tip cell activity in ECs. CCN1 is expressed in most cell types but not in ECs after development ([@bib74]). It is expressed in the front of the sprouting retina vessel, as previously reported ([@bib19]), and it functions in both paracrine and autocrine manner ([@bib51]; [@bib61]; [@bib47]). For the first time, after we confirmed that CCN1 is expressed only in tip cells in an autocrine manner, we revealed the mechanism by which tip cell activity is sustained. We treated cells with recombinant CCN1 primarily to mimic paracrine CCN1. In addition, we used EC-specific *Ccn1*-overexpressing mice to observe the function of endothelial CCN1. In recent research focusing on the role of some genes in blood vessels, mice with EC-specific gene knockout (KO) have generally been used; however, since the target gene in this case was more weakly expressed in ECs than in other surrounding cells, we cannot rule out the possibility that EC-specific KO phenotypes may be affected by proteins expressed in the other cell types, especially when studying a secreted protein, such as CCN1. Therefore, even though the results from EC-specific KO mice demonstrate dramatic effects on abnormal vascular formation, it is crucial to figure out the endogenous functions of genes on the basis of their expression patterns.

It has been reported that CCN1 does not induce the proliferation of fibroblasts or ECs ([@bib43]), suggesting that CCN1 cannot enhance stalk cell phenotype, as seen in our experiments. Expression of *VEGFR2, DLL4* and *SOX17* was significantly induced by CCN1 or VEGF. These findings are in agreement with a recent report that SOX17/VEGFR2 constitutes a feedback loop activated by VEGF signalling ([@bib40]). SOX17 is a transcription factor expressed in tip cells that enhances developmental angiogenesis ([@bib53]). Therefore, we speculate that CCN1 is involved in vascular sprouting by increasing the SOX17-VEGFR2 feedback loop, resulting in tip cell rather than stalk cell specification.

Direct physical interactions between purified CCN1 and integrin αvβ3 have already been observed in cell-free systems, and the EC adhesion induced by CCN1 is mediated by its binding to integrin αvβ3 ([@bib45]). In fact, several members of the CCN protein familyinduce angiogenic processes, such as proliferation, chemotaxis, and tube formation in ECs, through binding to integrin αvβ3 ([@bib4]; [@bib48]). In ECs, we found that CCN1 induced interactions between CCN1, integrin αvβ3, and VEGFR2. These interactions may then influence tip cell formation and tip cell activity induced by CCN1, indicating that CCN1 functions as a matricellular protein that mediates cell--matrix communication ([@bib81]). In addition, reactivation of Hippo pathway in several cancers on inhibition of integrin linked kinase ([@bib70]) and repressed CCN1 on targeted inhibition of integrin αvβ3 suppressing the metastasis in osteosarcoma ([@bib33]) suggested interplay of integrin αvβ3 and Hippo signalling but this is the first time to show the CCN1 mediated feedback loop through integrin αvβ3/YAP/TAZ axis in vascular sprouting.

Here, we demonstrated that CCN1 plays a key role in the induction of tip cell identity in EC sprouting. The inhibition of DLL4 in tip cells induces a loss of Notch signalling and is associated with an increase in VEGFR2 and VEGFR3 in stalk cells ([@bib71]; [@bib75]). The inhibition of DLL4/Notch signalling causes large vessels and increases vascular density in tumours ([@bib55]). The loss of CCN1 in ECs appears to inhibit DLL4/Notch signalling, even in the presence of VEGF, in retinal vessel formation ([@bib19]). Therefore, we speculate that CCN1 may increase tip cell activity via the DLL4/Notch signalling pathway. Interestingly, CCN1 increases the expression of both DLL4 (a negative feedback regulator of VEGF) and SOX17 (a positive regulator of VEGF). Thus, CCN1 may be a key molecule modulating VEGF signalling, either in the presence or absence of VEGF. Therefore, it is likely that the involvement of CCN1 in the activation of VEGFR2 is a key link in VEGFR2 feedback regulation ([@bib40]).

The increased phosphorylation of VEGFR2 (Y1175) caused by the loss of CCN1 in ECs ([@bib19]) may induce EC proliferation because of the dual roles of Y1175 phosphorylation in both EC proliferation and EC migration. Our results reflect the paracrine effects of CCN1 treatment on the Y1175 phosphorylation of VEGFR2 in EC migration, initiated by tip cells ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). Y1054 phosphorylation, involved in tyrosine kinase activity, clearly led to CCN1-mediated increases in VEGFR2 kinase activity levels, thus enhancing downstream signalling and leading to the expression of tip cell marker protein DLL4.

Accumulating evidence indicates the existence of many overlapping roles for CCN1 and VEGF in vascular formation ([@bib28]; [@bib47]). Recently, it was reported that EC-specific targeting of CCN1 increased the proliferation of retina ECs, resulting in dense and enlarged vascular networks that lacked the normal arrangement of arterioles, capillaries, and venules ([@bib19]). Hyperplasia of ECs and an increased venule diameter can be explained by enhanced stalk cell activity. Additionally, increased numbers of filopodia and decreased DLL4 signalling activity have been observed in the frontal cells of the retina following EC-specific *Ccn1* KO, suggesting that loss of CCN1 in ECs disturbs the Notch/DLL4 signalling pathway ([@bib19]). Thus, CCN1 may distinctly regulate the activities of tip cells and stalk cells.

Disrupting angiogenic vessel formation, either by inhibition of VEGF itself or by inhibition of the VEGF signalling pathway, limits targeting efficiency due to increases in intratumoural hypoxia and the induction of other growth factors, such as basic fibroblast growth factor (bFGF), stromal-derived factor 1 (SDF-1), and Tie-2 ([@bib66]). Furthermore, DLL4/Notch signalling has been found to mediate this resistance ([@bib55]). Novel and successful methods for targeting tumour angiogenesis have recently been developed. For example, combining anti-VEGF signalling therapy with an EGFR inhibitor ([@bib50]) or kinase inhibitors ([@bib62]) improves clinical outcomes. Thus, studies of specialised endothelial tip, stalk, and phalanx cell in developing sprouting vessels may provide approaches for eliminating resistance to anti-VEGF therapy (Avastin) and increasing the efficiency of treatments for angiogenic diseases.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent\                         Designation                                                                                                   Source or\                                                                           Identifiers                                                            Additional\
  type(species)\                                                                                                                                 reference                                                                                                                                                   information
  or resource                                                                                                                                                                                                                                                                                                
  -------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------------------- -----------------------------
  Antibody                         anti-Flk1(VEGFR2) (A-3)\                                                                                      Santa Cruz                                                                           sc6251\                                                                WB(1:1000)
                                   (Mouse monoclonal)                                                                                                                                                                                 RRID:[AB_628431](https://scicrunch.org/resolver/AB_628431)             

  Antibody                         anti-DLL4(H-70)\                                                                                              Santa Cruz                                                                           sc28915 RRID:[AB_2092978](https://scicrunch.org/resolver/AB_2092978)   WB(1:1000)
                                   (Rabbit polyclonal)                                                                                                                                                                                                                                                       

  Antibody                         anti-Sox17\                                                                                                   R and D Systems                                                                      AF1924\                                                                WB(1:1000)
                                   (Goat polyclonal)                                                                                                                                                                                  RRID:[AB_355060](https://scicrunch.org/resolver/AB_355060)             

  Antibody                         anti-p-VEGFR2 (Tyr1059)(D5A6)\                                                                                Cell Signalling                                                                      3817\                                                                  WB(1:1000)
                                   (Rabbit monoclonal)                                                                                                                                                                                RRID:[AB_2132351](https://scicrunch.org/resolver/AB_2132351)           

  Antibody                         anti-p-VEGFR2 (Tyr1175) (19A10)\                                                                              Cell Signalling                                                                      2478\                                                                  WB(1:1000)
                                   (Rabbit monoclonal)                                                                                                                                                                                RRID:[AB_331377](https://scicrunch.org/resolver/AB_331377)             

  Antibody                         anti-p-ERK1/2 (Thr202/Tyr204) (197G2)\                                                                        Cell Signalling                                                                      4377\                                                                  WB(1:1000)
                                   (Rabbit monoclonal)                                                                                                                                                                                RRID:[AB_331775](https://scicrunch.org/resolver/AB_331775)             

  CyeAntibody                      anti-ERK1/2 (137F5)\                                                                                          Cell Signalling                                                                      4695\                                                                  WB(1:1000)
                                   (Rabbit monoclonal)                                                                                                                                                                                RRID:[AB_390779](https://scicrunch.org/resolver/AB_390779)             

  Antibody                         anti-p-p38 (Thr180/Tyr182)\                                                                                   Cell Signalling                                                                      9211\                                                                  WB(1:1000)
                                   (Rabbit polyclonal)                                                                                                                                                                                RRID:[AB_331641](https://scicrunch.org/resolver/AB_331641)             

  Antibody                         anti-p38 (A-12)\                                                                                              Santa Cruz                                                                           sc7972\                                                                WB(1:1000)
                                   (Mouse monoclonal)                                                                                                                                                                                 RRID:[AB_620879](https://scicrunch.org/resolver/AB_620879)             

  Antibody                         anti- p85α (Z-8)\                                                                                             Santa Cruz                                                                           sc423\                                                                 WB(1:1000)
                                   (rabbit polyclonal)                                                                                                                                                                                RRID:[AB_632211](https://scicrunch.org/resolver/AB_632211)             

  Antibody                         anti- p-PI3-kinase p85 α (Tyr 508)\                                                                           Santa Cruz                                                                           sc12929\                                                               WB(1:1000)
                                   (goat polyclonal)                                                                                                                                                                                  RRID:[AB_2252313](https://scicrunch.org/resolver/AB_2252313)           

  Antibody                         anti-CCN1\                                                                                                    Abcam                                                                                Ab24448\                                                               WB(1:1000) IHC (1:200)
                                   (Rabbit polyclonal)                                                                                                                                                                                RRID:[AB_2088724](https://scicrunch.org/resolver/AB_2088724)           

  Antibody                         anti-CCN1\                                                                                                    Novus Biologicals                                                                    NB100-356\                                                             (1:1000) neutralization
                                   (Rabbit polyclonal)                                                                                                                                                                                RRID:[AB_10000986](https://scicrunch.org/resolver/AB_10000986)         

  Antibody                         anti-integrin αvβ3\                                                                                           Novus Biologicals                                                                    NB600-1342\                                                            WB(1:1000)
                                   (Mouse monoclonal)                                                                                                                                                                                 RRID:[AB_10003443](https://scicrunch.org/resolver/AB_10003443)         

  Antibody                         anti-p-STAT-3 (Tyr705) (D3A7) (Rabbit monoclonal)                                                             Cell signalling                                                                      9145\                                                                  WB(1:1000)
                                                                                                                                                                                                                                      RRID:[AB_2491009](https://scicrunch.org/resolver/AB_2491009)           

  Antibody                         anti-p-STAT1(Tyr701)\                                                                                         Cell signalling                                                                      9167\                                                                  WB(1:1000)
                                   (58D6)\                                                                                                                                                                                            RRID:[AB_561284](https://scicrunch.org/resolver/AB_561284)             
                                   (Rabbit monoclonal)                                                                                                                                                                                                                                                       

  Antibody                         anti-STAT3 (79D7)\                                                                                            Cell signalling                                                                      4904\                                                                  WB(1:1000)
                                   (Rabbit monoclonal)                                                                                                                                                                                RRID:[AB_331269](https://scicrunch.org/resolver/AB_331269)             

  Antibody                         anti-STAT1\                                                                                                   Cell signalling                                                                      9172\                                                                  WB(1:1000)
                                   (Rabbit polyclonal)                                                                                                                                                                                RRID:[AB_2198300](https://scicrunch.org/resolver/AB_2198300)           

  Antibody                         anti-p-YAP (Ser127)\                                                                                          Cell signalling                                                                      4911\                                                                  WB(1:1000)
                                   (Rabbit polyclonal)                                                                                                                                                                                RRID:[AB_2218913](https://scicrunch.org/resolver/AB_2218913)           

  Antibody                         anti-YAP/TAZ (D24E4) (Rabbit monoclonal)                                                                      Cell signalling                                                                      8418\                                                                  WB(1:1000)
                                                                                                                                                                                                                                      RRID:[AB_10950494](https://scicrunch.org/resolver/AB_10950494)         

  Antibody                         anti-p-LATS1 (Thr1079)(D57D3) (Rabbit monoclonal)                                                             Cell signalling                                                                      8654\                                                                  WB(1:1000)\
                                                                                                                                                                                                                                      RRID:[AB_10971635](https://scicrunch.org/resolver/AB_10971635)         IF (1:200)

  Antibody                         anti-LATS1(C66B5)\                                                                                            Cell signalling                                                                      3477\                                                                  WB(1:1000)
                                   (Rabbit monoclonal)                                                                                                                                                                                RRID:[AB_2133513](https://scicrunch.org/resolver/AB_2133513)           

  Antibody                         Alexa-488--conjugated anti-isolectin B4                                                                       Invitrogen                                                                           I21411\                                                                IHC (1:200)
                                                                                                                                                                                                                                      RRID:[AB_2314662](https://scicrunch.org/resolver/AB_2314662)           

  Antibody                         anti-VEGF\                                                                                                    R and D Systems                                                                      AF564\                                                                 (1:1000) neutralization
                                   (Goat polyclonal)                                                                                                                                                                                  RRID:[AB_2212821](https://scicrunch.org/resolver/AB_2212821)           

  Antibody                         anti-vinculin (EPR8185)\                                                                                      Abcam                                                                                ab196579\                                                              IF (1:200)
                                   (Rabbit monoclonal)                                                                                                                                                                                RRID:[AB_2810877](https://scicrunch.org/resolver/AB_2810877)           

  Antibody                         Cdc42\                                                                                                        Cell signalling                                                                      8747\                                                                  WB(1:1000)
                                   (Mouse monoclonal)                                                                                                                                                                                 RRID:[AB_2810881](https://scicrunch.org/resolver/AB_2810881)           

  Antibody                         Integrin β3 blocking IgG\                                                                                     Millipore                                                                            MAB1976\                                                               Neutralization
                                   (Mouse monoclonal)                                                                                                                                                                                 RRID:[AB_2296419](https://scicrunch.org/resolver/AB_2296419)           

  Antibody                         Anti-GFP (B-2)\                                                                                               Santa Cruz                                                                           sc9996\                                                                WB(1:1000)
                                   (Mouse monoclonal)                                                                                                                                                                                 RRID:[AB_627695](https://scicrunch.org/resolver/AB_627695)             

  Antibody                         anti-CD31\                                                                                                    BD Biosciences                                                                       553370\                                                                IF (1:200)
                                   (Mouse monoclonal)                                                                                                                                                                                 RRID:[AB_2638986](https://scicrunch.org/resolver/AB_2638986)           

  Antibody                         Anti-CD34\                                                                                                    Boster                                                                               PA1334\                                                                IF (1:200)
                                   (Rabbit polyclonal)                                                                                                                                                                                RRID:[AB_2810878](https://scicrunch.org/resolver/AB_2810878)           

  Antibody                         Anti-DLL4\                                                                                                    R and D systems                                                                      MAB1389\                                                               IF (1:200)
                                   (Rat-monoclonal)                                                                                                                                                                                   RRID:[AB_2092985](https://scicrunch.org/resolver/AB_2092985)           

  Other                            Alexa-488-phalloidin                                                                                          Invitrogen                                                                           A12379                                                                 IHC (1:200)

  Chemical compound, drug          JNK Inhibitor II anthra\[1,9 cd\]pyrazol-6(2H)-one-1,9-pyrazoloanthrone (SP600125)                            Calbiochem                                                                           420119                                                                 

  Chemical compound, drug          P38 MAP Kinase Inhibitor 4-(4-fluorophenyl)−2-(4-methylsulfinylphenyl)−5-(4-pyridyl)1H-imidazole (SB203580)   Calbiochem                                                                           559389                                                                 

  Chemical compound, drug          2′-amino-3′-methoxyflavone (PD98059)                                                                          Calbiochem                                                                           513000                                                                 

  Chemical compound, drug          2-(4-morpholinyl)−8-phenyl-4H-1-benzopyran-4-one (LY294002)                                                   Calbiochem                                                                           440202                                                                 

  Chemical compound, drug          Verteporfin                                                                                                   Sigma-Aldrich                                                                        SML0534                                                                

  Chemical compound, drug          Cyclo(RGDfK)                                                                                                  Selleckchem                                                                          S7834                                                                  

  Peptide recombinant protein      CCN1                                                                                                          R and D Systems                                                                      4055                                                                   

  Peptide recombinant protein      Vitronectin                                                                                                   Corning                                                                              354238                                                                 

  Peptide recombinant protein      fibronectin                                                                                                   Corning                                                                              354008                                                                 

  Commercial assay, or kit         Active Cdc42 detection kit                                                                                    Cell Signalling                                                                      11859                                                                  

  Recombinant DNA reagent          pEG-DIAPH1                                                                                                    Pro Jung Weon Lee (College of Pharmacy, Seoul National University)                                                                                          

  Recombinant DNA reagent          pEG-DIAPH1 ΔN3                                                                                                Prof. Jung Weon Lee (College of Pharmacy, Seoul National University)                                                                                        

  Recombinant DNA reagent          pGL3-CCN1\                                                                                                    This paper                                                                                                                                                  Progenitors: PCR, pGL3
                                   (cloned on VE-cadherin promoter)                                                                                                                                                                                                                                          

  Recombinant DNA reagent          pGL3-DLL4 luciferase plasmid                                                                                  Prof. Young Geun Kwon\                                                                                                                                      
                                                                                                                                                 Yonsei University                                                                                                                                           

  Recombinant DNA reagent          pRL-SV40 plasmid                                                                                              Promega                                                                              E2231                                                                  

  Sequence-based reagent           siRNA:siCCN1                                                                                                  Qiagen                                                                               SI03053477\                                                            
                                                                                                                                                                                                                                      SI03028655\                                                            
                                                                                                                                                                                                                                      SI02626428\                                                            
                                                                                                                                                                                                                                      SI02626421                                                             

  Sequence-based reagent           siRNA: siIntegrin β3                                                                                          Qiagen                                                                               SI02664095\                                                            
                                                                                                                                                                                                                                      SI02628094\                                                            
                                                                                                                                                                                                                                      SI00034188\                                                            
                                                                                                                                                                                                                                      SI00034174                                                             

  Sequence-based reagent           Negative control siRNA                                                                                        Qiagen                                                                               SI03650325                                                             

  Cell line\                       HUVEC                                                                                                         ATCC                                                                                 CRL-1730\                                                              
  (*H. sapiens*)                                                                                                                                                                                                                      RRID:[CVCL_2959](https://scicrunch.org/resolver/CVCL_2959)             

  Cell line\                       EA.hy926                                                                                                      ATCC                                                                                 CRL-2922\                                                              
  (*H. sapiens*)                                                                                                                                                                                                                      RRID:[CVCL_3901](https://scicrunch.org/resolver/CVCL_3901)             

  Cell line\                       LCC                                                                                                           ATCC                                                                                 CRL-1642\                                                              
  (*M. musculus*)                                                                                                                                                                                                                     RRID:[CVCL_4358](https://scicrunch.org/resolver/CVCL_4358)             

  Transgenic mice                  *Ccn1*-TG (Chd5:Ccn1, C57BL/6J)                                                                               Macrogen, Seoul, Korea                                                                                                                                      

  Transgenic zebrafish\            hemizygous TG (*flk*-1:*EGFP*)^s843^                                                                          Korea Zebrafish Organogenesis Mutant Bank (ZOMB) at Kyungpook National University\                                                                          
  (*D. rerio*)                                                                                                                                   [@bib38]                                                                                                                                                    

  Sequence-based reagent           *ccn1* MO (*D. rerio*)\                                                                                       Gene-Tools, Philomath                                                                                                                                       ccn1-l2, ENSDARG00000099985
                                   5′-CTCCGCTGACACACACACACAGGAC-3′                                                                                                                                                                                                                                           

  Software, algorithm              Prism                                                                                                         Graphpad Software                                                                    RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)           

  Software, algorithm              ImageJ                                                                                                        <https://imagej.nih.gov/ij/>                                                         RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)           

  Software, algorithm              edgeR package                                                                                                 <http://www.bioconductor.org./help/search/index.html?q=edger+package/>\              RRID:[SCR_012802](https://scicrunch.org/resolver/SCR_012802)           
                                                                                                                                                 [@bib67]                                                                                                                                                    

  Software, algorithm              quantile normalisation                                                                                        <http://bioconductor.org>\                                                           RRID:[SCR_001786](https://scicrunch.org/resolver/SCR_001786)           
                                                                                                                                                 [@bib12]                                                                                                                                                    

  Software, algorithm              Kaplan--Meier estimation                                                                                      <https://www.xlstat.com/en/solutions/features/kaplan-meier-analysis>\                                                                                       
                                                                                                                                                 [@bib9]                                                                                                                                                     

  NCI Genomic Data Commons (GDC)   Data Portal                                                                                                   <https://gdc-portal.nci.nih.gov>\                                                                                                                           
                                                                                                                                                 [@bib30]                                                                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Zebrafish strains and MO-mediated gene knockdown in zebrafish {#s4-1}
-------------------------------------------------------------

Wild-type AB strain and Tg(*flk-1:EGFP*)^s843^ zebrafish were used in this study ([@bib38]). Adult Zebrafish and embryos were raised at 28°C on a 14 hr light and 10 hr dark cycle. The two kinds of *ccn1* MO was synthesised by Gene-Tools (Philomath, OR, USA) with the following sequence: ccn1l2 splicing MO: 5′-CTCCGCTGACACACACACACAGGAC-3′, ccn1l2 ATG MO: 5'-TCCTCTGATTTCTTCCAGAATGCAT-3' (ccn1-l2, ENSDARG00000099985). For control MO, prepared control oligo provided from Gene-Tools was used with the following sequence: Standard MO: 5'- CCTCTTACCTCAGTTACAATTTATA-3'. All of the MOs was suspended in Nuclease-Free deionized water and injected into 1 cell stage TG embryos. Blood vessels were observed under a Nikon A1 plus confocal microscope or under a ZEISS Axioskop confocal microscope (Oberkochen, Germany). For sense RNA synthesis, *ccn1* cDNA was ligated into pCS2 vector, linearized by Not I restriction enzyme and transcribed by Sp6 RNA polymerase provided from Invitrogen mMESSAGE kit. *ccn1* sense RNA was injected into 1 cell stage TG embryos with ccn1l2 splicing MO.

Whole mount in situ hybridization in zebrafish {#s4-2}
----------------------------------------------

Embryos were fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) overnight, rinsed with PBST (0.1% Triton X-100 in PBS), transferred to methanol, and stored at −20°C until use. After rehydration with PBST, embryos were incubated with proteinase K solution. Embryos were refixed with 4% PFA for 20 min and then washed with PBST four times. Embryos were then pre-hybridised and hybridised at 65--67°C with antisense RNA probes. Subsequently, non-binding antisense RNA probes were washed, and embryos were transferred to blocking solution (5% sheep serum) for 2 hr at room temperature (RT). An alkaline phosphatase-conjugated sheep anti-digoxigenin Fab′ fragment (Roche, Basel, Switzerland) was added (1:4000 dilution) and incubated for 3 hr. Embryos were then washed five times with PBST for 15 min each at RT and then 2 times for 15 min each with staining buffer. Next, BCIP/NBT was added, and embryos were incubated at RT until staining.

Cell culture {#s4-3}
------------

HUVECs (ATCC, Manassas, VA, USA) were cultured on gelatine-coated (1% gelatine, Sigma-Aldrich) tissue culture plates in EBM2 (Lonza, Basel, Switzeland) supplemented with EGM2 kit and 20% foetal bovine serum (FBS, Hyclone) in a humidified atmosphere of 5% CO~2~ at 37°C. Human endothelial EA.hy926 cells (ATCC) were maintained in DMEM with 10% FBS and 1 × antibiotics.

Immunofluorescent assays {#s4-4}
------------------------

Aorta, spheroids or cells after treatment with or without CCN1 were fixed with 4% paraformaldehyde (PFA) and incubated overnight with primary antibodies. The next day, they were washed several times and further incubated with secondary antibodies with specific fluorescent probes and visualised using a confocal microscope (Leica TCS SP5 II Dichroic/CS, Germany).

siRNA-mediated gene knockdown in ECs {#s4-5}
------------------------------------

A pool of four distinct siRNAs directed against *CCN1* and *ITGB3* was purchased from Qiagen (Valencia, CA, USA). HUVECs were transfected with *CCN1* and *ITGB3* siRNA using a microporator (Invitrogen). Gene silencing was examined by performing semiquantitative RT-PCR at 24 hr after transfection.

Matrix adhesion assays {#s4-6}
----------------------

HUVECs were suspended in serum-free M199 medium and allowed to adhere to vitronectin (5 µg/mL, Corning)- or fibronectin (1 µg/mL, Corning)-coated and 0.1% BSA/PBS-blocked 96-well plates in the presence or absence of integrin β3 blocking IgG (1 µg/mL, Millipore) for 90 min. After washing with PBS, adhered ECs were stained with Crystal Violet for 10 min and lysed with 1% SDS, and the absorbance (O.D.) was measured at 550 nm.

Tube formation assay {#s4-7}
--------------------

HUVECs were seeded in a 48-well Matrigel (10 mg/mL, BD Biosciences, San Diego, CA, USA)-coated culture plate for 30 min at 37°C. Tube formation was observed for 12 hr, and the numbers of branching points in the tubular structures were counted under a microscope and photographed at 100 × magnification. Two or three independent experiments were performed and statistically analysed.

Aortic ring assay {#s4-8}
-----------------

An aortic arch obtained from 6 week-old C57BL/6J WT or *Ccn1*-TG mice was cut into \~1.0 mm pieces. The aortic rings were placed in 48-well Matrigel or collagen-coated plates. Then, 100 μL of EBM-2 medium containing VEGF or CCN1 was added to each well. The formation of vascular sprouts was observed after 7 days. The ECs expressing with DLL4, CD34 and CD31 were determined as tip cells by immunofluorescent assay and counted under the confocal microscope (Leica TCS SP5 II Dichroic/CS, Germany).

Spheroid sprouting assay {#s4-9}
------------------------

HUVECs (4 × 10^3^) were mixed with a 1.2% methylcellulose solution (Sigma-Aldrich) and M199 medium containing 0.1% FBS. The cell suspension was distributed into a 96-well U-shaped culture plate (BD Biosciences) and cultured overnight. The next day, the spheroids were harvested and mixed with diluted rat tail collagen (BD Biosciences). One millilitre of the spheroid-containing collagen solution was aliquoted into each well of a pre-warmed 24-well culture plate. After 1 hr for polymerization of the collagen at 37°C, VEGF or CCN1 was applied to the polymerized collagen gel, and endothelial sprouting was observed and fixed with 4% PFA for IF after 48 hr.

Wound migration assay {#s4-10}
---------------------

Confluent EA.hy926 cells in 12-well plates (Corning) were starved in 1% FBS in DMEM for 12 hr and treated with mitomycin C (0.5 μg/mL) for 1 hr. A wound was made with a pipette tip, and the cell debris was removed by washing with serum-free medium. The cells were treated with VEGF (10 ng/mL), CCN1 (10 ng/mL), or DMSO vehicle. The number of cells that moved beyond the injury line was counted. Three independent experiments were performed.

Matrigel plug assay {#s4-11}
-------------------

Matrigel (300 µL, BD Biosciences) was inoculated subcutaneously into both flanks of WT or EC-specific *Ccn1*-TG (*Chd5:Ccn1*) mice treated with vehicle or cyclo(RGDfK) (20 mg/kg). Matrigel plugs were removed at 7 days after inoculation and fixed with 4% paraformaldehyde (PFA, pH 7.4). Serial sections (8 µm) were stained with H and E and observed under a light microscope (Zeiss). The vessel density in each section was quantified after taking pictures, and the erythrocyte-containing vessel area was measured based on image analysis using ImageJ (National Institutes of Health, Bethesda, MD, USA).

Western blotting analysis {#s4-12}
-------------------------

Proteins were separated by SDS-PAGE and transferred to a nitrocellulose membrane (Whatman, Maidstone, UK). The membrane was blocked with 5% non-fat milk in Tris-buffered saline (TBS) containing 0.1% Tween-20 for 30 min at RT. The membrane was incubated with primary antibody at 4°C overnight and then with horseradish peroxidase-conjugated secondary antibodies for 1 hr. The membrane was visualised using West Pico Chemiluminescent Substrate (PIERCE, Woburn, MA, USA).

Semiquantitative and real-time RT-PCR {#s4-13}
-------------------------------------

Total RNA was extracted from cultured cells using TRIzol Reagent (Invitrogen). cDNA synthesis from total RNA was performed using a first-strand cDNA synthesis kit for reverse transcription-PCR according to the manufacturer's protocol (TOYOBO, Osaka, Japan). The cDNA was used as a template for PCR using specific primers for *CCN1* (forward, 5′-GAGCACATGTTACTGCTTCA-3′; reverse, 5′-GATAGCTGCCTCTCACAGAC-3′) and *zEF-1a* (forward, 5′-GCAAGGAGAAGACCCACATC-3′; reverse, 5′-CTTGAACCTCGGCATGTTG-3′). The conditions for semiquantitative PCR were 30 cycles of denaturation (94°C for 30 s), annealing (50°C for 40 s), and extension (72°C for 40 s), followed by a final extension (72°C for 10 min). Real-time PCR was performed using a Bio-Rad Real-Time PCR system with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). The specific primer sequences for real-time PCR are shown in [Table 1](#table1){ref-type="table"}.

10.7554/eLife.46012.022

###### Gene primer sequences for qPCR.

  Gene name   Forward                       Reverse
  ----------- ----------------------------- -----------------------------
  *DLL4*      ATTCGTCACCTGGATCCTTC          TCATTCTGGGCCAGTTGTAA
  *SOX17*     CAGACTCCTGGGTTTTTGTTGTTGCTG   GAAATGGAGGAAGCTGTTTTGGGACAC
  *ROBO4*     GACGGGAATCAGAACCACTT          CAGAGAAACACAGGCCAAGA
  *VEGFR2*    CTCGGGTCCATTTCAAATCT          GCTGTCCCAGGAAATTCTGT
  *JAG1*      AAGGCTTCACGGGAACATAC          AGCCGTCACTACAGATGCAC
  *NOTCH1*    AAGATGCTCCAGCAACACAG          GGCTCTGGCAAGTCTCCTAC
  *β-actin*   GGATGTCCACGTCACACTTC          CACTCTTCCAGCCTTCCTTC
  *DIAPH1*    CAAGACAACCTCTTGTGCCC          GCTCCGAAGCTAGCAGAGAT

In situ PLA {#s4-14}
-----------

To confirm the presence of protein--protein interactions, HUVECs were fixed with 4% PFA for 15 min and PLA was performed following the manufacturer\'s instructions (Sigma-Aldrich). Briefly, chamber slides were blocked; incubated with anti-VEGFR2, anti-CCN1, and anti-integrin β3 antibodies; and then incubated with PLA probes overnight at 4°C. After washing, cells were incubated with the respective secondary antibodies conjugated with the PLA probe for 1 hr at 37°C, washed, and ligated for 30 min at 37°C. Subsequently, amplification with polymerase was performed for 100 min at 37°C. To detect the nuclei of the HUVECs, 4\'−6-diamidino-2-phenylindole (DAPI) was used for staining for 1 min at RT, and the slides were mounted using Vectashield (Vector Laboratories, Burlingame, CA, USA). Red fluorescence signals were visualised with a confocal laser scanning microscope (LSM 700, Zeiss). The number of red dots in each cell was quantified using ImageJ.

Dual luciferase reporter assay {#s4-15}
------------------------------

HUVECs were transfected with *pGL3-DLL4* luciferase and *Renilla* luciferase pRL-SV40 plasmids by electroporation (Thermo Fisher Scientific, Waltham, MA, USA). One day after transfection, cells were treated with VEGF (10 ng/mL) or CCN1 (10 ng/mL) in the presence or absence of cyclo(RGDfK) (5 μM) for 24 hr. Luciferase assays were performed using a Dual-Glo Luciferase Reporter Assay System (Promega).

Detection of active Cdc42 {#s4-16}
-------------------------

HUVECs were seeded at a density of 2 × 10^5^ in a 100 mm dish. The next day, cells were transfected with empty vector, *DIAPH1* WT, or *DIAPH1* double negative mutant for 24 hr and further starved overnight. Then, cells were treated with PBS or CCN1 (10 ng/mL) for 30 min. Protein lysate was collected by centrifugation at 16,000 × *g* at 4C for 15 min. Active Cdc42 was extracted from the lysate per the manufacturer's protocol. Briefly, an equal amount of protein was used for GTPase assay (Active Cdc42 detection kit, 8819, Cell Signalling Technology). GST-PAK1-PBD fusion protein was used to bind the activated form of GTP-bound Cdc42. The level of activated Cdc42 was checked by WB with Cdc42 antibody (Cell Signalling Technology).

Generation of *Ccn1*-TG mice {#s4-17}
----------------------------

The *Cdh5* (VE-cadherin) promoter fragment was cloned according to a strategy previously described ([@bib68]; [@bib39]) in a pGL3 basic vector (Promega, Madison, WI, USA). Briefly, after using PCR for synthesis with an additional restriction site, *EcoR*V following *Sma*I, *Cdh5* promoter fragments were inserted between the *Sac*I and *Sma*I sites. The mouse cDNA was synthesised from total RNA, and the *Ccn1* fragments were amplified by PCR with primers including the restriction sites *EcoR*V/*Xba*I at each end and inserted into a *Cdh5* promoter-cloned pGL3 vector. TG mice were generated by microinjection of the *Cdh5* promoter-driven *Ccn1* expression plasmid into fertilised C57BL/6 mouse oocytes. Following microinjection, the oocytes were transferred to the oviducts of pseudo-pregnant C57BL/6 females (Macrogen, Seoul, Korea). To identify TG mice, genomic DNA was extracted from the mouse tails and amplified using PCR with primers targeting the middle of the *Cdh5* promoter to the middle of the *Ccn1* gene. C57BL/6 mice (Japan SLC, Inc, Hamamatsu, Japan) were maintained under specific pathogen-free conditions with a constant humidity and temperature at 26 ˚C, filtered air and a 12/12 hr light/dark cycle. Mice were treated with CO~2~ by inhalation in a chamber for anaesthesia, immediately prior to sacrifice.

In vivo tumour allograft experiment and IHC {#s4-18}
-------------------------------------------

LLC cells (2 × 10^5^) were injected subcutaneously into the right and left flanks of 6-week-old WT and *Ccn1*-TG (*Chd5:Ccn1*) C57BL/6J mice. When the tumour mass reached around 500 mm^3^, we excised the mass and fixed it with 4% PFA. After tissues were processed for frozen sample preparation, samples were embedded in OCT compound and frozen quickly by liquid nitrogen. Frozen blocks were cut into 50 µm sections, blocked with 5% goat serum in PBST (0.03% Triton X-100 in PBS), and then incubated for 3 hr at RT with primary antibodies.

Patient survival analysis and mRNA expression correlation {#s4-19}
---------------------------------------------------------

To evaluate the correlation between mRNA expression levels of *CCN1* and patient survival in several cancers including LUSC, we first collected read counts for 60,483 gene features for 502 primary tumour samples of LUSC, 375 samples of STAD, and 414 samples of BLCA from the NCI Genomic Data Commons (GDC) Data Portal ([@bib30]). The read counts were normalised using the TMM normalisation method in the edgeR package ([@bib67]); the normalised counts were converted to log~2~ read-counts after adding one to the normalised counts, and the log~2~ read-counts were further normalised using the quantile normalisation method ([@bib12]). Finally, we divided the samples into two groups, encompassing the top and bottom 25% of patients with the highest and lowest mRNA expression levels based on the normalised log~2~ read-counts and evaluated differences in survival between the two groups using the log-rank test with Kaplan--Meier estimation ([@bib9]).

IHC for retinal angiogenesis analysis {#s4-20}
-------------------------------------

Retinas were incubated with or without anti-CCN1 antibody (Abcam) overnight. After washing several times, the samples were incubated for four hat RT with Alexa Fluor488-conjugated isolectin B4 (IB4, Invitrogen) and anti-rabbit Alexa Fluor 647-conjugated IgG. The whole-mount retinas were visualised and digital images obtained using a Leica TCS SP5 II Dichroic/CS confocal microscope (Leica, Wetzlar, Germany). The number of front tip cells with filopodia was counted in three different peripheral fields of the retina. The radial length of the blood vessels in the postnatal retina was measured as the shortest distance from the optic nerve head to the peripheral vascular front in each retinal quadrant. The vascular density in the whole-mounted retina was calculated as the IB4^+^ microvessel area divided by the total measured area of the retina and presented as a percentage.

Statistical analysis {#s4-21}
--------------------

ANOVA was used to assess the significance of intergroup differences. For the quantification of the IHC data, one-way analysis of variance with Newman-Keuls multiple comparison test. A *p*-value\<0.05 was considered statistically significant and noted in each Figure legend, and results are represented as means ± standard deviations (SD). Transcript data from human cancer database (from GDC) was analyzed with t-test after edgeR package was employed for genomic data analysis. Overall survival rate was evaluated using log-rank test with Kaplan--Meier estimation. The correlation of mRNA expression levels between nine angiogenesis marker genes and *CCN1* in three cancers (LUSC, BLCA, and STAD) was estimated by Spearman's rank correlation (Spearman's rho) and empirical testing using the following procedure. For each cancer, we first randomly selected two genes among the total expressed genes and computed Spearman's rho between two genes. This random selection was repeated 100,000 times, resulting in 100,000 random Spearman's rho values. We then estimated an empirical null distribution for the Spearman's rho by applying the Gaussian kernel density estimation method ([@bib15]) to the 100,000 random Spearman's rho values. Finally, the p-value for the observed Spearman's rho was computed by the right-sided test using the empirical distribution.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Cyr61 interlinks integrin and Hippo pathway to autoregulate tip cell activity\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jonathan Cooper as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Hong Chen (Reviewer \#2).

It would be important for authors to either show a CRISPR/Cas9 phenotype or to perform a rescue experiment -- that is to use a MO that targets the endogenous gene but not a rescue construct, and put both in and show a rescue. A more detailed quantitative analysis of the overall state of the embryos subjected to morpholinos relative to controls would also strengthen this work.

Major points:

1\) The conclusion of the present study on the role of Cyr61 in angiogenesis is inconsistent with a previous study (Chintala et al., 2015). It is possible that the vascular phenotypes could differ, given that the present study and the previous study have employed different approaches (gain-of-function versus loss-of-function). However, it is still necessary to reconcile this disparate results/conclusion with more convincing evidences. For example, examining the vascular phenotypes in the EC-specific Cyr61-deleted mouse would be a definitive approach.

2\) The reviewers raised numerous issues and errors in imaging presentation, descriptions, and statistical analyses. The authors should carefully go through their manuscript and correct them. Moreover, there were several technical issues that could be solved with better and advanced approaches.

*Reviewer \#1:*

While the presented study is interesting, it is mainly based in vitro observation. The in vivo experiments performed in Zebrafish and mouse would require further work and characterization to completely support the proposed model by the authors.

In particular, in the last sentence of the Results section the authors write: Our results indicate that Cyr61 expression induced by activated YAP/TAZ increases tip cell activity in ECs via filopodial formation mediated by the mDi1 Roh effector.\" Cyr61 increases activation of VEGFR2, ERK1/, P38 MAPK and PI3K signaling pathways by binding with integrin alphavbeta3 and VEGFR2. These signalling pathways subsequently induce YAP/TAZ activity and Cyr61 expression, sustaining tip cell activity in ECs (Figure 8)\". Even if Cyr61 is not highly expressed in retina tip cells, the authors should generate the EC-specific knockout mice in order to clearly confirm their proposed model.

*Reviewer \#2:*

The investigators of this manuscript reported that Cyr61 positively regulated endothelial tip cell activation and promoted angiogenesis through integrin αvβ3 and YAP/TAZ pathway and its potential clinical implications on the survival of cancer patients. Thus, the area of research holds substantial translational value and clinical relevance. The idea to study the role of integrin αvβ3 and YAP/TAZ pathway in mediating the effect of Cyr61 on angiogenesis is original. The experimental design was logical with the usage of Zebrafish MO and of endothelial cell-specific Cyr61 transgenic mice. A variety of studies were used to confirm endothelial tip cell function and angiogenesis in vivo and in vitro. The investigators also analyzed human patient data from NCI Genomic Data Commons (GDC) Data Portal with lung squamous cell carcinoma, bladder urothelial cancer, and stomach adenocarcinoma to establish the reverse relationship between patient survival and Cyr61 expression. These data were strong and supportive to the conclusion in general. However, the in-depth mechanisms underlying how Cyr61 modulates activity of integrin αvβ3 and signaling capacity of VEGFR2 is less clear. Further, Zebrafish MO studies need to be complemented with rescue experiments or knockout approaches.

Additionally, there are a few concerns in the manuscript that need to be addressed.

1\) Very little data were provided on the patients including age, sex, stage of cancer, other critical medical conditions like DM, HTN, coronary artery disease that may have a substantial impact on the survival. The labeling in Figure 7C and Figure 7---figure supplement 1A and C (Days to death) appeared to be wrong; the mean survival age needs to be indicated. Information of basal time point for the survival curve needs to be explained whether \"0\" indicates the date of diagnosis, surgery, or treatment.

2\) The authors stated that Cyr61 was only expressed in tip cells in an autocrine manner, not in stalk cells. It was also not produced in endothelial cells after development. It would be nice to include discussion regards the differences between tip cells and stalk cells and the potential mechanisms regulating its expression.

3\) WB results lack statistical analyses and some blots do not reflect the results. It would be helpful to replace with better representative and unsaturated gel bands throughout the manuscript.

4\) Image data appeared to be adjusted artificially and inappropriately. For example, integrin β3 signal in the merged image does not reflect or display information shown in the corresponding single channel (Figure 5---figure supplement 1C).

5\) The description for the statistical method is unclear. The statistical analysis section needs to be addressed more appropriately. For instance, \"Analysis of variance\" means \"ANOVA\" where it indicated as two different approaches. IHC data was indicated where one-way ANOVA with post-hoc test was used. Authors need to explain how other experiments were analyzed. Some experiments contain two groups where One-way ANOVA may not be suitable for statistical analysis. Figure 2C and Figure 5E have two groups and should be analyzed by t-test. Transcript data from human cancer database (from GDC) should be analyzed with t-test if edgeR or DESeq was employed for genomic data analysis.

6\) Many places showed the unaligned or different thickness of error bars within the graphs, which need to be fixed (Figure 2A, 2B, 2C, 2E, 3B, 5B, G, H, I). Also, there are missing error bars in some place (Supplemental figure B).

7\) VEGFR2 was used as an internal loading control after VEGF or Cyr61 stimulation. VEGFR2 is not a proper loading control as VEGFR2 phosphorylation can induce VEGFR2 internalization and degradation.

8\) Since α-SMA is expressed in smooth muscle cells and myofibroblasts. α-SMA alone is not a solid pericyte marker (Figure 7A). Therefore, the conclusion that Cyr61TG decrease pericyte coverage is overstating. PDGFR-β or NG2 should be used for validating pericyte coverage in transplanted tumor section.

9\) Materials and methods and resource table showed that BAECs were used in this study (subsection "Cell culture" and key resources table). However, BAECs had not been used throughout the study. It would be nice to state which experiments BAECs were used.

10\) In Figure 1 legend, it should be \"intron 1/exon2\" as indicated in text and schematic figure, not \"intron2/exon3 boundary\".

*Reviewer \#3:*

This paper by Kim et al. investigates the angiogenic function of cyr61 (CCN1) using numerous in vivo and in vitro models. They conclude that cyr61 induces tip cells by working thru VEGFR and integrin signaling, and they place YAP/TAZ in the signaling axis. Although there are some potentially interesting insights provided, there are significant concerns with both novelty, significance, and methodology that significantly diminish enthusiasm.

1\) The overall novelty is not considered high, and the work is predicted to have moderate to minimal impact on the field. It is known that Cyr61 is involved in angiogenesis, and a 2015 Development paper (cited) describes an angiogenic loss-of-function phenotype suggesting that Cyr61 negatively regulates VEGFR2 and integrin signaling with some underlying mechanism. This work\'s unique aspect of YAP/TAZ involvement is predicted from recent work of others showing that YAP/TAZ regulates angiogenesis.

2\) The premise for the experiments is not always clear. EC cell-autonomy vs. non cell-autonomy for Cyr61 function is often interchanged, so it is not clear how the authors interpret their data. Most experiments are gain of function and show that exogenous protein or EC-specific expression increase sprouting parameters, yet Chintala et al. showed that vascular-specific deletion of CCN1 also lead to increased sprouting, and this apparent discrepancy is not explained. The authors claim little to no endothelial expression of cyr61, but Chintala et al. showed expression at the angiogenic front. The single in vivo loss-of-function experiment uses only one Zfish morpholine, and the phenotype is pleiotropic without a rescue, so in my opinion cannot be interpreted. Thus the premise for the work is not strong. The authors assume that \"tip cell\" is a fate, not a phenotype, and use primarily 2D EC cultures to look at perturbations they associate with \"tip cells\".

3\) There are numerous methodological issues that weaken the work. For example, the Zfish experiment cannot be interpreted as the embryos are severely compromised and there is no rescue done; the aortic ring assay does not use a marker to distinguish endothelial cells from other cells that also sprout; the spheroid assay is not robust and does not form luminized vessels in controls; the assay for filopodia is primarily done in 2D, where it is not clear what is measured or how filopodia are normalized.

10.7554/eLife.46012.026

Author response

> Major points:
>
> 1\) The conclusion of the present study on the role of Cyr61 in angiogenesis is inconsistent with a previous study (Chintala et al., 2015). It is possible that the vascular phenotypes could differ, given that the present study and the previous study have employed different approaches (gain-of-function versus loss-of-function). However, it is still necessary to reconcile this disparate results/conclusion with more convincing evidences. For example, examining the vascular phenotypes in the EC-specific Cyr61-deleted mouse would be a definitive approach.

Thank you for your valuable comment. As for these concerns, [first,]{.ul} many previous publications showed and suggested that CCN1 (Cyr61) enhances angiogenesis (reviewed in (Jun and Lau, 2011)), consistent with our results, but inconsistent with another study (Chintalaet al., 2015). CCN1 stimulates cell migration or chemotaxis in fibroblasts and endothelial cells, and promote the invasiveness of certain cancer cells (Chen and Lau, 2009). CCN1, CCN2 and CCN3 are functioning through direct binding to integrin αvβ3 in endothelial cells to promote proliferation and induce chemotaxis and formation of tubules (Babicet al., 1998; Kubota and Takigawa, 2007; Jun and Lau, 2011). The previous publications found that these CCNs may be involved in embryonic development, inflammatory diseases and tumorigenesis through their angiogenic activities (Kubota and Takigawa, 2007; Kularet al., 2011).

In addition, Ccn1 enhances tumor growth through its potent angiogenic activity (Babicet al., 1998), accordingly, forced expression of Ccn1 in breast cancer cells promotes tumor growth in xenografts with increased vascularization (Xieet al., 2001; Tsaiet al., 2002). The results are correlated with our results for LLC allograft mouse tumor model (Figure 7A-B) and TCGA big data analysis (Figure 7D).

Second, a question struck in our mind, if *CCN1* is rarely expressed in ECs after birth but expressed in other CNS cells and fibroblast (Kireevaet al., 1997), in *Ccn1*-EC-specific KO mouse, other cells can secrete CCN1 into ECs which can bind to integrin αvβ3 leading to the increased angiogenesis. Hence, the increased angiogenesis in *Ccn1*-EC-specific KO mouse is not likely owing to the inhibitory function of CCN1 towards angiogenesis via inhibition of VEGFR2 activity in ECs (Chintala et al., 2015), but is likely to the angiogenic function of the secreted CCN1 from non-EC cells where it might have been expressed. Thus, EC-specific KO for certain protein which is rarely expressed in EC but fairly expressed in non-ECs cannot demonstrate the role of that protein in EC if it is secreted, which we have discussed in "Discussion" part in our manuscript.

Chintala et al., 2015, also showed that Ccn1 is expressed only in the front area of the retina, but scarcely expressed in other retinal vascular ECs at p5. This expression pattern in retina may support our results for the autonomous activation of tip cells through the YAP/TAZ (which are expressed in retinal vessels at P5 (Kimet al., 2017)) activity induced by Ccn1 (Figure 3 and 5). Also EC-specific KO of Lats (an upstream inhibitor or YAP/TAZ) in mice showed the significant increase in "*Ccn1* expression signature" in ECs (Kimet al., 2017), suggesting that YAP/TAZ activation increases Ccn1 in the front region of retinal vessels.

In conclusion, we would like to suggest that our approaches of in vitro study and in vivo EC-specific transgenic mouse are towards the right direction to identify the exact role of CCN1 in angiogenic process. Therefore, lots of evidences from our in vitro and in vivo research with CCN1 on ECs as well as the role of YAP/TAZ, upstream regulator of CCN1, in sprouting angiogenesis, indicate that CCN1 is the angiogenic inducer as a tip cell activator but not the angiogenic inhibitor.

Third, unfortunately, currently we do not have the mouse system for inducible EC-specific deletion of *Ccn1*, however, we have the zebrafish system for showing the role of ccn1 in endothelial cells. Also, due to the reasons mentioned above, we adopted two different strategies as below to confirm our results, rather than an EC-specific KO mice adopted by Chintala et al., 2015.

Zebrafish knockdown system with another type of morpholino against *ccn1* (targeting ATG transcription starting site) in vascular specific GFP-expressing embryos was performed. We obtained the vascular defects same as the results from previous morpholino targeting splicing region (between the intron 1/exon 2 boundary) (Figure 1C).

We confirmed these results with a rescue experiment by microinjecting *ccn1* cRNA and obtained the results with normal vascular development (Figure 1C).

> 2\) The reviewers raised numerous issues and errors in imaging presentation, descriptions, and statistical analyses. The authors should carefully go through their manuscript and correct them. Moreover, there were several technical issues that could be solved with better and advanced approaches.

Thank you very much for kind directions for the errors. It was the initial submission recommended by *eLife* for initial review process. We solved the issues and problems raised by reviewers by responding each reviewer's comments.

> Reviewer \#1:

*While the presented study is interesting, it is mainly based* in vitro *observation. The in vivo experiments performed in Zebrafish and mouse would require further work and characterization to completely support the proposed model by the authors.*

> In particular, in the last sentence of the Results section the authors write: Our results indicate that Cyr61 expression induced by activated YAP/TAZ increases tip cell activity in ECs via filopodial formation mediated by the mDi1 Roh effector.\" Cyr61 increases activation of VEGFR2, ERK1/, P38 MAPK and PI3K signaling pathways by binding with integrin alphavbeta3 and VEGFR2. These signalling pathways subsequently induce YAP/TAZ activity and Cyr61 expression, sustaining tip cell activity in ECs (Figure 8)\". Even if Cyr61 is not highly expressed in retina tip cells, the authors should generate the EC-specific knockout mice in order to clearly confirm their proposed model.

Thank you for your valuable comment. We were allowed to do the zebrafish morpholino (MO) using additional MO and rescue experiments within 3 months by Associate Editor, as we do not have the mouse system for inducible EC-specific deletion of *Ccn1* unfortunately, but, we have the zebrafish system for showing the role of ccn1 in endothelial cells. Due to the reasons mentioned above, we adopted two different strategies as below to confirm our results, rather than an EC-specific KO mice.

Zebrafish knockdown system with another type of morpholino against *ccn1* (targeting ATG transcription starting site) in vascular specific GFP-expressing embryos was adopted. We obtained the vascular defects same as the results from previous morpholino targeting splicing region (between the intron 1/exon 2 boundary) and added the results in Figure 1C (V-VI) and Figure 1D.

We confirmed these results with a rescue experiment by microinjecting *ccn1* cRNA and got normal vascular development results and images (Figure 1C, VII-VIII) and Figure 1D.

As a result, we found the sprouting defects of vasculature both in ATG morpholino (MO) (Figure 1C, V-VI) and in splicing region of intron1/exon2 site (Figure 1C, III-IV), respectively. And these sprouting defects were significantly rescued by the sense mRNAof *ccn1* (Figure 1C, VII-VIII). These results showed that ccn1 is responsible for the sprouting of vessel formation.

Reviewer \#2:

*The investigators of this manuscript reported that Cyr61 positively regulated endothelial tip cell activation and promoted angiogenesis through integrin αvβ3 and YAP/TAZ pathway and its potential clinical implications on the survival of cancer patients. Thus, the area of research holds substantial translational value and clinical relevance. The idea to study the role of integrin αvβ3 and YAP/TAZ pathway in mediating the effect of Cyr61 on angiogenesis is original. The experimental design was logical with the usage of Zebrafish MO and of endothelial cell-specific Cyr61 transgenic mice. A variety of studies were used to confirm endothelial tip cell function and angiogenesis* in vivo *and* in vitro*. The investigators also analyzed human patient data from NCI Genomic Data Commons (GDC) Data Portal with lung squamous cell carcinoma, bladder urothelial cancer, and stomach adenocarcinoma to establish the reverse relationship between patient survival and Cyr61 expression. These data were strong and supportive to the conclusion in general. However, the in-depth mechanisms underlying how Cyr61 modulates activity of integrin αvβ3 and signaling capacity of VEGFR2 is less clear. Further, Zebrafish MO studies need to be complemented with rescue experiments or knockout approaches.*

In this paper, we checked only for the involvement of integrin αβ heterodimer not for the integrin α subunit specifically, because the previous publications suggest that integrin αvβ heterodimers play role in CCN1-induced proangiogenic activity. In a previous report, CCN1 has 20 AA residues (NCKHQCTCIDGAVGCIPLCP) which are binding sites for integrin αvβ3 for its proangiogenic activity (Chenet al., 2004). As mentioned in the Results section, β1 integrin is known to be involved in the tubular formation of migration of ECs by CCN1, but involvement of β1 was not found in the adhesion induced by CCN1 (Figure 5---figure supplement 1). We, thus, investigated the interaction between integrin αvβ3 and CCN1, VEGFR2 and integrin αvβ3 as well as CCN1. We then used specific peptide inhibitor against integrin αvβ3, cyclo (RGDfK), which binds specifically and with high affinity to αvβ3 to inhibit its activity (Lucieet al., 2009; Limet al., 2018). Cyclo (RGDfK) treated ECs abolished CCN1-treated VEGFR2 signaling pathway and Yap/Taz activation. Therefore, we concluded that VEGFR2 signaling pathways are activated by CCN1 via binding of integrin αvβ3/VEGFR2/CCN1. However, in-depth mechanism underlying how CCN1 modulates integrin ɑ and VEGFR2 activity is to be identified in separate further studies.

> Additionally, there are a few concerns in the manuscript that need to be addressed.
>
> 1\) Very little data were provided on the patients including age, sex, stage of cancer, other critical medical conditions like DM, HTN, coronary artery disease that may have a substantial impact on the survival. The labeling in Figure 7C and Figure 7---figure supplement 1A and C (Days to death) appeared to be wrong; the mean survival age needs to be indicated. Information of basal time point for the survival curve needs to be explained whether \"0\" indicates the date of diagnosis, surgery, or treatment.

As suggested, we obtained clinical information of the patients from the original papers. Also, we assessed whether clinical parameters (age, sex, and stage of cancer) could have substantial impacts on the survival by performing 1) Student's t-test to compare ages between *CCN1* high and *CCN1* low patient groups and 2) proportion tests for proportions of sex or stage of cancer in *CCN1* high and *CCN1* low patient groups. Age showed no significant difference between *CCN1* high or *CCN1* low patient group in LUSC and STAD cohorts. Also, none of sex and stage of cancer was significantly enriched in either *CCN1* high or *CCN1* low patient group in LUSC and STAD cohorts. Given that *CCN1* high and *CCN1* low patient groups showed significant difference in the survival, these data suggest that these parameters appear to have no significant impacts on patient survival. Interestingly, however, in BLCA, age and stage of cancer showed significant (P\<0.05) difference or enrichment between *CCN1* high and *CCN1* low patient groups, suggesting potential association of age and stage of cancer with patient survival in BLCA. On the other hand, we could find other medical conditions including DM, HTN, and coronary artery disease from the original papers (TCGA data portal and supplementary tables) and thus could not assess potential impacts of these conditions on patient survival through the aforementioned proportional tests for their enrichments in either *CCN1* high or *CCN1* low patient group in LUSC, STAD, and BLCA cohorts. In the revised manuscript, we added the descriptions for these results in Results section (Figure 7---figure supplement 1).

Moreover, as suggested, we changed the x-axis label "Days to death (year)" in Figure 7C and Figure 7---figure supplement 1C to "Years after diagnosis". We also included the mean survival age (mean OS; estimated as the area under the survival curve) of each patient group. Basal time point ("0") for the survival curve indicates the date of the initial pathological diagnosis. We added this information to figure legends.

> 2\) The authors stated that Cyr61 was only expressed in tip cells in an autocrine manner, not in stalk cells. It was also not produced in endothelial cells after development. It would be nice to include discussion regards the differences between tip cells and stalk cells and the potential mechanisms regulating its expression.

We discussed as much as possible about the differences between tip cells and stalk cells and the potential mechanisms regulating its specification by CCN1 in the Discussion section.

> 3\) WB results lack statistical analyses and some blots do not reflect the results. It would be helpful to replace with better representative and unsaturated gel bands throughout the manuscript.

We performed Western blot (WB) analysis in Figure 3B again, quantified with previous blot data and graphed as shown in Figure 3B right panel. Other WB data were quantified and denoted as a Fold change value below each western band because of the space limitation.

> 4\) Image data appeared to be adjusted artificially and inappropriately. For example, integrin β3 signal in the merged image does not reflect or display information shown in the corresponding single channel (Figure 5---figure supplement 1C).

Merged images are adjusted darker than the integrin β3 signals. We corrected it.

> 5\) The description for the statistical method is unclear. The statistical analysis section needs to be addressed more appropriately. For instance, \"Analysis of variance\" means \"ANOVA\" where it indicated as two different approaches. IHC data was indicated where one-way ANOVA with post-hoc test was used. Authors need to explain how other experiments were analyzed. Some experiments contain two groups where One-way ANOVA may not be suitable for statistical analysis. Figure 2C and Figure 5E have two groups and should be analyzed by t-test. Transcript data from human cancer database (from GDC) should be analyzed with t-test if edgeR or DESeq was employed for genomic data analysis.

We described in detail the statistical analysis for the data with different approaches at the Materials and methods section. We used t-test for Figure 7D for the transcript analysis as reviewer indicated and added this in Materials and methods section as a "Statistical analysis" as well as in a part of figure legend.

> 6\) Many places showed the unaligned or different thickness of error bars within the graphs, which need to be fixed (Figure 2A, 2B, 2C, 2E, 3B, 5B. G, H, I). Also, there are missing error bars in some place (Supplemental figure B).

We corrected unaligned graphs as well as graph format in all Figures.

> 7\) VEGFR2 was used as an internal loading control after VEGF or Cyr61 stimulation. VEGFR2 is not a proper loading control as VEGFR2 phosphorylation can induce VEGFR2 internalization and degradation.

We used β-actin for a loading control in all Western blot analysis.

> 8\) Since α-SMA is expressed in smooth muscle cells and myofibroblasts. α-SMA alone is not a solid pericyte marker (Figure 7A). Therefore, the conclusion that Cyr61TG decrease pericyte coverage is overstating. PDGFR-β or NG2 should be used for validating pericyte coverage in transplanted tumor section.

We used the PDFGR-β instead of α-SMA for validating pericyte coverage in transplanted tumor section.

> 9\) Materials and methods and resource table showed that BAECs were used in this study (subsection "Cell culture" and key resources table). However, BAECs had not been used throughout the study. It would be nice to state which experiments BAECs were used.

After we used BAECs in the preliminary experiments, we changed the cells into HUVECs to do in vitro tube formation assay and obtained results shown in this manuscript. Therefore, we omitted this cells from the table.

> 10\) In Figure 1 legend, it should be \"intron 1/exon2\" as indicated in text and schematic figure, not \"intron2/exon3 boundary\".

We corrected into intron 1/exon2.

> Reviewer \#3:
>
> This paper by Kim et al. investigates the angiogenic function of cyr61 (CCN1) using numerous in vivo and in vitro models. They conclude that cyr61 induces tip cells by working thru VEGFR and integrin signaling, and they place YAP/TAZ in the signaling axis. Although there are some potentially interesting insights provided, there are significant concerns with both novelty, significance, and methodology that significantly diminish enthusiasm.
>
> 1\) The overall novelty is not considered high, and the work is predicted to have moderate to minimal impact on the field. It is known that Cyr61 is involved in angiogenesis, and a 2015 Development paper (cited) describes an angiogenic loss-of-function phenotype suggesting that Cyr61 negatively regulates VEGFR2 and integrin signaling with some underlying mechanism. This work\'s unique aspect of YAP/TAZ involvement is predicted from recent work of others showing that YAP/TAZ regulates angiogenesis.

Thank you for your valuable comment. We responded these issues as described in the "Major points" from the Reviewing Editor above. Here we underscored the positive feedback regulation of tip cells by CCN1 and identified the signalling pathway from the membrane to transcription factor, YAP/TAZ in the nucleus. Formation or specification of tip cell should be continued among the ECs during active angiogenesis. Like stem cells, tip cells having migrating property may have to make stalk cells that follow them by dividing. Or only stalk cells are dividing behind the tip cells. Because the dynamic changes of Notch signalling as well as resultant genetic modification in migrating and extending cells, we still do not know exactly whether and how a cell at the topmost is maintained as a tip cell. We adopted the in vitro cell culture system where an angiogenic factor was applied to the whole culture media with the same concentration. Genetic changes or behaviour of ECs by the same manner even the migrating phenotypes were different. Therefore, we determined the expression level of tip cell markers as well as YAP/TAZ activity as a master regulator of tip cell. A receptor of CCN1, integrin αvβ3 made it associated into VEGFR2 to transfer signalling for activation of YAP/TAZ.

*2) The premise for the experiments is not always clear. EC cell-autonomy vs. non cell-autonomy for Cyr61 function is often interchanged, so it is not clear how the authors interpret their data. Most experiments are gain of function and show that exogenous protein or EC-specific expression increase sprouting parameters, yet Chintala et al. showed that vascular-specific deletion of CCN1 also lead to increased sprouting, and this apparent discrepancy is not explained. The authors claim little to no endothelial expression of cyr61, but Chintala et al. showed expression at the angiogenic front. The single* in vivo *loss-of-function experiment uses only one Zfish morpholine, and the phenotype is pleiotropic without a rescue, so in my opinion cannot be interpreted. Thus the premise for the work is not strong. The authors assume that \"tip cell\" is a fate, not a phenotype, and use primarily 2D EC cultures to look at perturbations they associate with \"tip cells\".*

Thank you for your valuable comment. We responded and performed the rescue experiment as described in "Response" to the "Major points" from the Associate Editor above. We tried to clarify the premise for the experiment in the whole manuscript as solid as possible, especially the EC-cell autonomy for CCN1 function.

At the beginning of research, in zebrafish knockdown experiments, we found that ccn1 has a role in the migration and sprouting of ECs during vascular development. Then using in vitro EC culture system, we identified the genetic changes of markers for specific ECs as well as the migrating ability after CCN1 was treated. Next, we investigated CCN1 induced YAP/TAZ and VEGFR2 activity, key regulators of vascular sprouting, and further signaling circuit to induce CCN1 again. Therefore, we emphasize that CCN1 may activate YAP/TAZ to induce target gene, CCN1 again for maintaining the tip cell properties. It was a gradual outcome, and our final conclusion was the auto-regulation by CCN1 in tip cells.

And we described and emphasized that CCN1 is expressed only in retina frontal EC, but not much in whole EC in the second paragraph of the Introduction section. And then we raised a question in the Results section about the discrepancy that CCN1 deletion increases sprouting even if it is expressed only in the frontal ECs in the subsection "CCN1 promotes endothelial sprouting activity in angiogenesis"..

> 3\) There are numerous methodological issues that weaken the work. For example, the Zfish experiment cannot be interpreted as the embryos are severely compromised and there is no rescue done; the aortic ring assay does not use a marker to distinguish endothelial cells from other cells that also sprout; the spheroid assay is not robust and does not form luminized vessels in controls; the assay for filopodia is primarily done in 2D, where it is not clear what is measured or how filopodia are normalized.

Thank you for your valuable comment. We responded these issues as described in the "Major points" from the Reviewing Editor above. For the sprouting assay, we perform it again with 3D culture system.

[^1]: These authors contributed equally to this work.
